Photoredox-Catalyzed Aminofluorosulfonylation of Unactivated Olefins

Tao Zhong, Ji-Tao Yi, Zhi-Da Chen, Quan-Can Zhuang, Yong-Zhao Li, Gui Lu, and Jiang Weng*

Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yatsen University, Guangzhou, 510006, P.R. China.

Table of Contents

I. General Information	S3
2. Typical Procedure for the Synthesis of Substrates	S3
3. Procedure for the Synthesis of Intermediates	\$5
1. Details for Optimization of Reaction Conditions	se
5. General Procedure for the Synthesis of Sulfonyl Fluorides	S12
6. Derivatization Reactions of Sulfonyl Fluorides	.S13
7. Mechanistic Experiments	S16
3. Stern-Volmer studies	.S19
). Large-scale Experiments	.S25
0. Characterization Data of Compounds 1d, 1e, 1l-1r, 1t-1ad, 1af-1ao, 2a-2ao, D1-D14, S5.	S26
I1. References	.\$48
12 NMR Spectra of Compounds 1d 1e 1l-1r 1t-1ad 1af-1ao 2a-2ao D1-D14 S5	S40

1. General Information

All the commercial reagents were used as such without further purification. All solvents were used as commercial anhydrous grade without further purification. The flash column chromatography was carried out over silica gel (230-400 mesh). 1 H, 13 C and 19 F NMR spectra were recorded on a Bruker Avance-300 MHz spectrometer or Bruker Avance-400 MHz spectrometer or Bruker Avance-500 MHz spectrometer. Chemical shifts in 1 H NMR spectra were reported in parts per million (ppm, δ) downfield from the internal standard Me₄Si (TMS, δ = 0 ppm). Chemical shifts in 13 C NMR spectra were reported relative to the central line of the chloroform signal (δ = 77.0 ppm). Peaks were labeled as singlet (s), doublet (d), triplet (t), quartet (q), and multiplet (m) Low resolution mass spectrometry (LRMS) was performed on a Fisons Platform spectrometer (ESI). High resolution mass spectrometry (HRMS) was performed via electron ionisation (EI) or electrospray ionisation (ESI) sources. The m/z ratios are reported in Daltons; high resolution values are calculated to four decimal places from the molecular formula. Chemical yields refer to pure isolated substances.

2. Typical Procedure for the Synthesis of Substrates

Method A:^[1] (Scheme S1). A flame-dried round-bottomed flask was degassed, flushed with nitrogen, and charged with dry DCM (6.25 mL, 0.4 M), EDC-HCI (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 3.25 mmol, 1.3 eq.), and DMAP (3.5 mmol, 1.4 eq.). The reaction flask was cooled to 0 °C and then the carboxylic acid (2.5 mmol, 1.0 eq.) was added. After five minutes of stirring, the substituted aniline (3 mmol, 1.2 eq.) was added. The ice bath was then removed and the reaction mixture was stirred overnight. Upon completion of reaction (monitored by TLC), the mixture was washed with 1 M HCl and the aqueous layer was extracted with dichloromethane or ethyl acetate for three times. The combined organic layer was washed with brine and dried with Na₂SO₄. The crude product was purified by silica gel column chromatography to afford the desired product.

Scheme S1. Preparation of aryl amide (Method A)

Method B: $^{(1)}$ (Scheme S2). A flame-dried round-bottomed flask was degassed, flushed with nitrogen, and charged with phenyl isocyanate (2.5 mmol, 1 eq.), dry DCM (5 mL), Et₃N (7.5 mmol, 1.1 eq.) and alcohol/amine (2.5 mmol, 1 eq.). The reaction mixture was stirred at room temperature until the alcohol/amine was fully consumed (monitored by TLC). The reaction mixture was washed with 1 M HCl, water and brine and then dried with Na₂SO₄. Then, the organic phase was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to afford the desired product.

Scheme S2. Preparation of phenyl Carbamate/urea (Method B)

$$Ar-NCO + R-XH \xrightarrow{Et_3N} Ar \xrightarrow{H} R$$

$$CI \xrightarrow{H} O \xrightarrow{CI} CI \xrightarrow{H} O \xrightarrow{CI} CI \xrightarrow{H} O$$

$$1ae \qquad 1af \qquad 1ag \qquad 1ah$$

$$1ai \qquad 1aj \qquad 1ak$$

Method C:^[2] (Scheme S3). A flame-dried round-bottomed flask was degassed, flushed with nitrogen, and charged with (3-carboxypropyl)triphenylphosphonium bromide (3 mmol, 1 eq.) and suspended in dry THF (1.0 M). The mixture was cooled to 0 °C followed by slow addition of NaHMDS (3 mL, 2.0 M in THF). After 30 minutes of stirring, the corresponding aldehyde was subsequently added dropwise into the reaction (3.6 mmol, 1.2 eq.). The reaction was left to slowly warm to room temperature overnight until starting material was consumed (monitored by TLC). The reaction mixture was quenched by a solution of saturated ammonium chloride solution and the pH was adjusted to 2 by addition of 2 M HCl. Then the aqueous layer was extracted with 50 mL ethyl acetate. After concentrating the organic phase, the residue was directly used in the next step without purification. The reaction flask was degassed, flushed with nitrogen, and charged with CDI (3 mmol, 1.0 eq.) and a solution of the corresponding carboxylic acid (1.0 eq.) in dry THF (1.0 M). After 1 h of stirring, the substituted aniline (3 mmol, 1.0 eq.) was added and the reaction mixture was subsequently stirred overnight. Upon completion of reaction (monitored by TLC), the reaction mixture was taken to dryness under reduced pressure. The crude product was purified by silica gel column chromatography to afford the desired product.

Scheme S3. Preparation of aryl amide (Method C)

3. Procedure for the Synthesis of Intermediates

S1 and **S2** was synthesized according to the method of literature. $^{[3]}$ n-BuLi (13 mL, 1.6 M in hexane, 21 mmol) was added dropwise to a cold (0 $^{\circ}$ C) solution of iPr₂NH (3.0 mL, 21 mmol) in THF (10 mL), and the mixture was stirred for 30 minutes. Then, a solution of carboxylic acid (10 mmol) in THF (10 mL) was added dropwise over 20 minutes and stirring was continued for another 30 minutes at the same temperature. Allyl bromide (0.9 mL, 10.5 mmol) was added, and the stirring was continued for another 6 h. The solvent was removed under reduced pressure. The resulting residue was diluted with water (50 mL) and extracted with ethyl acetate (50 mL). The pH value of the separated aqueous layer was adjusted to 2 by 6 M HCl and then extracted with ethyl acetate. The combined organic layers were washed with brine, dried with Na₂SO₄, and filtered. The solvent was evaporated, and the crude acid was taken forward to the next step without further purification.

\$3 was synthesized according to the method of literature. [4] To a solution of L-allylglycine (576 mg, 5 mmol) in THF/H₂O (10:1, 11 mL) at 0 °C were added Boc_2O (1.20 g, 5.5 mmol) and Na_2CO_3 (1.06 g, 10 mmol). The reaction was stirred for 16 h at room temperature, after which the reaction mixture was acidified to pH 2 with 2 M HCl and extracted with ethyl acetate. The combined organic layers were washed with brine, dried Na_2SO_4 , filtered, and the solvent was removed in vacuo to afford crude (S)-2-((tert-butoxycarbonyl)amino)pent- 4-enoic acid as a colorless oil.

S4 is synthesized according to the method of literature. ^[4] To a round-bottom flask equipped with a magnetic stir bar was added D/L-2-allylglycine (576 mg, 5 mmol). The flask was evacuated and back-filled with nitrogen three times, and Et₃N (1.39 mL, 10 mmol), toluene (33.3 mL, 0.15 M), and phthalic anhydride (1.481g, 10 mmol) were added. The flask was then fitted with a Dean–Stark

apparatus and refluxed at 140 $^{\circ}$ C for 16 h. The crude reaction mixture was then concentrated in vacuo, acidified with water and HCl, then extracted into ethyl acetate and washed with water. After concentrating in vacuo, the crude solid was dissolved in aqueous K_2CO_3 , washed with ether. The aqueous layer was acidified with HCl and extracted with ethyl acetate. The organic layers were dried over Na_2SO_4 and concentrated in vacuo to afford crude racemic **S4**.

4. Details for Optimization of Reaction Conditions

Table S1. Initial evaluation of solvents and fluorine sources (Na₂S₂O₅ as the SO₂ surrogate)

[[]a]: Reaction conditions: **1a** (0.1 mmol), **Na**₂**S**₂**O**₅ (0.2 mmol, 2.0 eq.), **F sources** (0.2 mmol, 2.0 eq.), PC, base in 1.0 mL solvent under N₂ atmosphere; [b]: ¹⁹F NMR yields calculated with PhCF₃ as internal standard;

Table S2. Initial evaluation of base

Entry ^[a]	Base (1.1 eq.)	Additive (1.5 eq.)	Solvent (1 mL)	Yield ^[b] (%)
1	DMAP (0.4 eq.)		MeCN	16
2	DMAP		MeCN	11
3	K₂CO₃		MeCN (2 mL)	21
4	Na ₂ HPO ₄		MeCN (2 mL)	trace
5	DMAP (0.4 eq.)	ТВАІ	MeCN (2 mL)	ND

[[]a]: Reaction conditions: 1a $\overline{(0.1 \text{ mmol})}$, Na₂S₂O₅ $\overline{(0.2 \text{ mmol}, 2.0 \text{ eq.})}$, Selectfluor $\overline{(0.2 \text{ mmol}, 2.0 \text{ eq.})}$, PC, base in MeCN under N₂ atmosphere; [b]: ¹⁹F NMR yields calculated with PhCF₃ as internal standard;

Table S3. Evaluation of base and flurine sources (DABSO as the SO₂ surrogate)

Entry ^[a]	SO ₂	F source	Base (1.1 eq.)	Solvent (2 mL)	Yield ^[b] (%)
1	DABSO	Selectfluor	DMAP	MeCN	trace
2	DABSO	Selectfluor	K₂CO₃	MeCN	trace
3	DABSO	NFSI	DMAP	MeCN	trace
4	DABSO	NFSI	K₂CO₃	MeCN	41
5	variation from	entry 4	without PC		N.D.
6	variation from	entry 4	without light		N.D.

[[]a]: Reaction conditions: $\overline{\mathbf{1a}}$ (0.1 mmol), **DABSO** (0.15 mmol, 1.5 eq.), **F sources** (0.2 mmol, 2.0 eq.), PC, base in 2.0 mL MeCN under $\overline{N_2}$ atmosphere; [b]: ¹⁹F NMR yields calculated with PhCF₃ as internal standard;

Table S4. Evaluation of varying amounts of the substrates

Entry ^[a]	DABSO	NFSI	Yield ^[b] (%)
1	1.0 eq.	2.0 eq.	28
2	2.0 eq.	2.0 eq.	30
3[0]	1.5 eq.	2.0 eq.	13
4	1.5 eq.	1.1 eq.	trace
5	1.5 eq.	1.5 eq.	42
6	1.5 eq.	2.0 eq.	45
7	1.5 eq.	2.5 eq.	44
8	1.5 eq.	3.0 eq.	45

[[]a]: Reaction conditions: 1a (0.1 mmol), DABCO (X eq.), NFSI (Y eq.), PC, K_2CO_3 (1.1 eq.) in 2.0 mL MeCN under N_2 atmosphere; [b]: ¹⁹F NMR yields calculated with PhCF₃ as internal standard; [c]: 0.5 mL H₂O was added.

Table S5. Further evaluation of the base

Entry ^[a]	Base (1.1 eq.)	Yield ^[b] (%)
1	K ₂ CO ₃	45
2	Na ₂ CO ₃	44
3	$K_3PO_4\cdot 3H_2O$	42
4	Et_3N	<10
5	Cs ₂ CO ₃	<20
6	КОН	33
7	DABCO	<20
8	Imidazole	33
9	KOAc	37
10	K ₂ HPO ₄	22
11	NaHCO ₃	22
12	K₃PO₄	48
13	CaCO ₃	34

[[]a]: Reaction conditions: 1a (0.1 mmol), DABSO (0.15 mmol, 1.5 eq.), NFSI (0.2 mmol, 2.0 eq.), PC, base in 2.0 mL MeCN under N_2 atmosphere; [b]: ¹⁹F NMR yields calculated with PhCF₃ as internal standard;

Table S6. Evaluation of the reaction concentration

Entry ^[a]	Base (1.1 eq.)	PC	Solvent 2 mL	Yield ^[b] (%)
1	K₃PO₄	1 mol%	MeCN	48
2	K ₃ PO ₄	1.5 mol%	MeCN	51
3	K ₃ PO ₄	2.0 mol%	MeCN	48
4	K ₃ PO ₄	1.5 mol%	MeCN (3 mL)	53
5	K ₃ PO ₄	1.5 mol%	MeCN (4 mL)	60
6	K ₃ PO ₄	1.5 mol%	MeCN (5 mL)	54
7	K ₃ PO ₄ (1.0 eq.)	1.5 mol%	MeCN (4 mL)	64
8	K ₃ PO ₄ (1.2 eq.)	1.5 mol%	MeCN (4 mL)	50
9	K ₃ PO ₄ (1.3 eq.)	1.5 mol%	MeCN (4 mL)	47
10	K₃PO₄ (1.5 eq.)	1.5 mol%	MeCN (4 mL)	48
11	K ₃ PO ₄ (2.0 eq.)	1.5 mol%	MeCN (4 mL)	49

[[]a]: Reaction conditions: **1a** (0.1 mmol), **DABSO** (0.15 mmol, 1.5 eq.), **NFSI** (0.2 mmol, 2.0 eq.), PC, base in MeCN under N₂ atmosphere; [b]: ¹⁹F NMR yields calculated with PhCF₃ as internal standard;

Table S7. Selected optimization experiments

PC-II 1.5 mol%
$$K_3PO_4$$
 (1.0 eq.)

The second representation from the standard conditions at least a standard conditions at least at least a standard conditions at least at least at least a standard conditions at least at l

entry	variation from the standard conditions ^[a]	yield (%) ^[b]
1	none	64 (60) ^[c]
2	PC-I instead of PC-II	30
3	PC-III instead of PC-II	45
4	4CzIPN instead of PC-II	50
5	Eosin Y instead of PC-II	N.D.
6	[Ru(bpy)₃]Cl₂ instead of PC-II	trace
7	Selectfluor instead of NFSI	trace
8	Na₂S₂O₅ instead of DABSO	trace
9	Rongalite instead of DABSO	N.D.
10	K₂CO₃ instead of K₃PO₄	55
11	$Bu_4N[OP(O)(OMe)_2]$ instead of K_3PO_4	trace
12	without PC 2	N.D.
13	without light	N.D.
14	without base	50

[[]a]: Reaction conditions: $\mathbf{1a}$ ($\overline{0.1}$ mmol), \mathbf{DABSO} (0.15 mmol, 1.5 eq.), \mathbf{NFSI} (0.2 mmol, 2.0 eq.), PC, K_3PO_4 in 4.0 mL MeCN under $\overline{N_2}$ atmosphere; [b]: ^{19}F NMR yields calculated with PhCF₃ as internal standard; [c]: Isolated yield.

5. General Procedure for the Synthesis of Sulfonyl Fluorides 2



General Procedure: Under N_2 atmosphere, a 10 mL reaction tube was charged with amides **1** (0.1 mmol, 1.0 eq.), DABSO (36.1 mg, 0.15 mmol, 1.5 eq.), NFSI (63.1 mg, 0.2 mmol, 2.0 eq.), $[Ir(dF(CF_3)ppy)_2(bpy)]PF_6$ (1.5 mg, 1.5 mol%), K_3PO_4 (21.3 mg, 0.1 mmol, 1.0 eq.) and MeCN (4.0 mL), and the reaction mixture was irradiated with two 12 W blue lamps and the heat from light was blown away by fan. After stirring at room temperature for 10 h, the reaction mixture was filtered through a pad of celite, eluted with ethyl acetate, concentrated, and purified by flash column chromatography (eluent: petroleum ether/ethyl acetate) on silica gel to give the desired product **2.**

6. Derivatization Reactions of Sulfonyl Fluorides

To an oven-dried sealed tube equipped with a magnetic stir bar were added sulfonyl fluoride 2a (25.7 mg, 0.1 mmol, 1.0 eq.), MeONa (27 mg, 0.5 mmol, 5 eq.) and methanol (0.5 mL) under N_2 atmosphere. The mixture was stirred at room temperature for 15 minutes. After removal of the solvent under reduced pressure with a rotary evaporator, the crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate 3:1) to give a white solid D1 (23.2 mg, 86% yield). [5]

O
$$C_{S_2}$$
 C_{S_2} $C_$

To a 5 mL glass vial were added sulfonyl fluoride 2a (25.7 mg, 0.10 mmol, 1.0 eq.), phenol (10.4 mg, 0.11 mmol, 1.1 eq.), Cs_2CO_3 (65.2 mg, 0.20 mmol, 2.0 eq.), followed by the addition of dry MeCN (0.5 mL). The reaction mixture was stirred at room temperature for 12 h to achieve full conversion. The crude reaction mixture was concentrated in vacuo and purified by flash chromatography (petroleum ether/ethyl acetate 5:1 to 3:1), giving the desired product as a white solid D2 (28.3 mg, 85% yield). [6]

To a solution of sulfonyl fluoride 2a (25.7 mg, 0.1 mmol, 1.0 eq.), TBS-protected mecarbinate (34.8 mg, 0.11 mmol, 1.1 eq.) in MeCN (1 mL) was added tetrabutylammonium fluoride (TBAF) (30 μ L, 0.03 mmol, 1 mol in THF) at room temperature. The mixture was stirred at room temperature until the completion of the reaction (2 h) as indicated by TLC. After the solvent was evaporated under vacuum, the residue was purified by flash column chromatography over silica gel (petroleum ether/ethyl acetate 3:1 to 1:1) to afford the product as a white solid **D3** (44 mg, 94%). [7]

In a 10 mL flask, sulfonyl fluoride 2a (42.5 mg, 0.165 mmol, 1.1 eq.) and TMS-protected alcohol ^[8] (49.9 mg, 0.15 mmol, 1.0 eq.) were dissolved in anhydrous MeCN (0.5 mL). DBU (4.6 mg, 4.5 μ L, 0.03 mmol, 0.2 eq.) was added under a positive nitrogen flow. The flask was sealed and stirred at room temperature for 2 h. The solvent was removed immediately, and the the crude reaction mixture was concentrate in vacuo and purified by flash chromatography (petroleum ether/ethyl acetate 3:1 to 2:1) to afford the pure triazole product as white solids $\mathbf{D4}$ (55 mg, 74% yield).

$$\begin{array}{c} O \\ O = S - F \\ O = S - NH_2 \\ \hline \\ NH_3 \cdot H_2O \\ \hline \\ Pyridine, MeCN \\ 60 \, ^{\circ}C, 4 \, h \\ \end{array}$$

To an oven-dried sealed tube equipped with a magnetic stir bar were added sulfonyl fluoride **2a** (51.5 mg, 0.2 mmol, 1.0 eq.), pyridine (31.7 mg, 0.4 mmol, 2.0 eq.), ammonium hydroxide (143 μ L, 2.0 mmol, 10 eq.) and MeCN (2 mL) under N₂ atmosphere. The mixture

was stirred at 60 °C for 4 h. After removal of the solvent under reduced pressure with a rotary evaporator, the crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate 1:1 to 0:1) to give a colorless oil **D5** (39.2 mg, 77% yield). [5]

Sulfonyl fluoride **2a** (25.7 mg, 0.10 mmol, 1.0 eq.) was added to a solution of morpholine (17.4 mg, 0.20 mmol, 2.0 eq.) and triethylamine (28 µL, 0.2 mmol, 2.0 eq.) in MeCN (0.1 mL). The reaction mixture was stirred at 80 °C for 24 h to achieve full conversion. The crude reaction mixture was concentrated in vacuo and purified by flash chromatography (petroleum ether/ethyl acetate 5:1 to 3:1) to give the product as a white solid **D6** (29.1 mg, 90% yield). [6]

To a solution of sulfonyl fluoride 2a (51.5 mg, 0.2 mmol, 1.0 eq.) in MeCN (0.4 mL) at 50 °C was added DMAP (36.7 mg, 0.3 mmol, 1.5 eq.) followed by TMSN₃ (20 μ L, 0.15 mmol). The solution was stirred at 50 °C for 15 minutes, then further two portions of TMSN₃ (20 μ L, 0.15 mmol) were added at intervals of 15 minutes. The solution was stirred for 6 h to achieve full conversion. The crude reaction mixture was concentrated in vacuo and purified by flash chromatography (petroleum ether/ethyl acetate 5:1 to 3:1) to give the product as a white solid **D7** (43 mg, 78% yield). [6]

To a dry toluene (0.4 mL) suspension of CuTC (1.9 mg, 0.01 mmol), was added alkyne (11 μL, 0.10 mmol, 1.0 eq.) with vigorous stirring. After 10 minutes, a toluene (0.1 mL) solution of sulfonyl azide **D7** (30.9 mg, 0.11 mmol, 1.1 eq.) was added dropwise over 15 minutes. The reaction was stirred at room temperature until complete consumption of the alkyne by TLC (24 h). The crude reaction mixture was concentrate in vacuo and purified by flash chromatography (petroleum ether/ethyl acetate 5:1) to afford the pure triazole product as white solids **D8** (27 mg, 71% yield). [6]

To a 10 mL Schlenk flask purged with N_2 gas was added sulfonyl fluoride **2d** (33.6 mg, 0.1 mmol, 1.0 eq.), $Pd(PPh_3)_4$ (5.8 mg, 0.005 mmol, 5 mol%), sodium carbonate (21.2 mg, 0.2 mmol, 2.0 eq.) and phenylboronic acid (22.8 mg, 0.15 mmol, 1.5 eq.). Then degassed anhydrous toluene (0.4 mL) and methanol (0.1 mL) was added by syringe. The reaction mixture was stirred at 95 °C for 12 h. After cooling to room temperature, the solvent was removed under vacuum, and the residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate 5:1) to afford the product as a white solid **D9** (10.9 mg, 30% yield) and the recovery **2d** (16.8 mg, 40%). [9]


To a solution of sulfonyl fluoride 2d (33.6 mg, 0.1 mmol, 1.0 eq.) in THF (0.5 mL) was added ethynyltrimethylsilane (51 µL, 0.36 mmol, 3.6 eq.), Et₃N (69.5 µL, 0.5 mmol, 5.0 eq.), and CuI (1.9 mg, 0.01 mmol, 10 mol%). The resulting mixture was stirred in glove box for 20 minutes, at which time $PdCl_2(PPh_3)_2$ (14.1 mg, 0.02 mmol, 20 mol%) was added. The reaction mixture was stirred overnight and then concentrated. Flash chromatography on silica gel (petroleum ether/ethyl acetate 5:1 to 3:1) afforded the product as a white solid D10 (7.0 mg, 20% yield) and the recovery 2d (13.4 mg, 40%). [10]

In a 5 mL flask, sulfonyl fluoride **2a** (42.5 mg, 0.165 mmol, 1.1 eq.), 9-BBN (0.44 mL, 0.22 mmol, 0.5 M in THF) were added in a glove box under a nitrogen atmosphere. The reaction mixture was heated to 65 °C. The reaction was complete after refluxing for 1 h. After cooling to room temperature, the solvent was removed under vacuum, and the residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate 20:1) to afford the product as a white solid **D11** (15 mg, 62% yield). [11]

7. Mechanistic Experiments


(1) Radical trapping experiments with TEMPO

Under N_2 atmosphere, a 10 mL reaction tube was charged with amide $\mathbf{1c}$ (0.1 mmol, 1.0 eq.), DABSO (36.1 mg, 0.15 mmol, 1.5 eq.), NFSI (63.1 mg, 0.2 mmol, 2.0 eq.), $[Ir(dF(CF_3)ppy)_2(bpy)]PF_6$ (1.5 mg, 1.5 mol%), K_3PO_4 (21.3 mg, 0.1 mmol, 1.0 eq.), TEMPO (94 mg, 0.6 mmol, 3 eq.) and MeCN (4.0 mL), and the reaction was carried out under the illumination of two 12 W blue lamps and the heat from light was blown away by fan. After stirring at room temperature for 10 h, TLC and LC-MS analysis demonstrated the sulfonyl fluoride $\mathbf{2c}$ is not founded, and the amidyl radical or γ -lactam bearing alkyl radical combined with TEMPO were detected by LC-MS.



(2) Radical trapping experiments with 1,1-diphenylethylene

Under N_2 atmosphere, a 10 mL reaction tube was charged with amide 1c (0.1 mmol, 1.0 eq.), DABSO (36.1 mg, 0.15 mmol, 1.5 eq.), NFSI (63.1 mg, 0.2 mmol, 2.0 eq.), $[Ir(dF(CF_3)ppy)_2(bpy)]PF_6$ (1.5 mg, 1.5 mol%), K_3PO_4 (21.3 mg, 0.1 mmol, 1.0 eq.), 1,1-diphenylethylene (108 mg, 0.6 mmol, 3 eq.) and MeCN (4.0 mL), and the reaction was carried out under the illumination of two 12 W blue lamps and the heat from light was blown away by fan. After stirring at room temperature for 10 h, TLC analysis demonstrated only a small amount of sulfonyl fluoride 2c was formed, and the D12 or D13 were determined by LC-MS. D14 was isolated in 33% yield.




1-(4-chlorophenyl)-5-(((2,2-diphenylvinyl)sulfonyl)methyl)pyrrolidin-2-one (D14)

Compound **D14** was prepared according to **General Procedure** with additional 1,1-diphenylethylene (108 mg, 0.6 mmol, 3 eq.). The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 3:1) to give a white solid (14.9 mg, 33% yield).

¹H NMR (400 MHz, CDCl₃) δ 7.46 - 7.37 (m, 2H), 7.38 - 7.28 (m, 8H), 7.22 (dd, J = 11.0, 4.0 Hz, 4H), 6.78 (s, 1H), 4.69 (ddd, J = 13.0, 6.2, 3.8 Hz, 1H), 2.96 (dd, J = 13.4, 1.7 Hz, 1H), 2.77 (dd, J = 13.4, 10.3 Hz, 1H), 2.57 - 2.43 (m, 3H), 2.19 (dt, J = 10.6, 9.0 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 173.8, 157.0, 138.7, 135.2, 135.1, 131.4, 131.0, 129.8, 129.8, 129.6, 128.9, 128.4, 128.3, 126.9, 124.0, 56.0, 53.8, 30.6, 24.6. **HRMS (ESI):** m/z calculated for [M] ($C_{25}H_{22}NO_3SCI$) from [M+H]⁺ is 452.1082, found 452.108

(3) Determination of the existence of nitrogen anion

Under N_2 atmosphere, a 10 mL reaction tube was charged with amide $\mathbf{1c}$ (0.1 mmol, 1.0 eq.), ethyl acrylate (0.15 mmol, 1.5 eq.), with or without K_3PO_4 (21.3 mg, 0.1 mmol, 1.0 eq.), MeCN (4.0 mL), and the reaction was carried out under the illumination of two 12 W blue lamps and the heat from light was blown away by fan. After stirring at room temperature for 10 h, TLC analysis demonstrated that with the help of K_3PO_4 , an aza-Michael product was formed, and only trace mount was formed without K_3PO_4 . [12] The aza-Michael product and amide $\mathbf{1c}$ couldn't be separated for their similar polarity, but it can be demonstrated in ¹H-NMR analysis as the following figure.



8. Stern-Volmer studies

Stern-Volmer studies were carried out with Fluoromax-4 (HORIBA Instruments Incorporated). Different solutions containing 0.2 mM **PC-II** and x mM substrates were irradiated at 370 nm and luminescence was measured at 473 nm.




Figure S1 Fluorescence quenching of the excited PC-II with each sample in MeCN

Samples were excited at 370 nm. **PC-II** (0.2 mM) in MeCN (black line), **PC-II** (0.2 mM) with **1a** (2.0 mM) in MeCN (red line), **PC-II** (0.2 mM) with **1a** and K₃PO₄ (2.0 mM) in MeCN (blue line), **PC-II** (0.2 mM) with **1a** and *t*-BuOK (2.0 mM) in MeCN (green line), **PC-II** (0.2 mM) with **NFSI** (2.0 mM) in MeCN (purple line), **PC-II** (0.2 mM) with **DABSO** (2.0 mM) in MeCN (brown line).




Figure S2 Fluorescence quenching of the excited PC-II with different concentrations of 1a





Figure S3 Fluorescence quenching of the excited PC-II with different concentrations of 1a and 1.0 eq. K₃PO₄



 $\textbf{Figure S4} \ \ \text{Fluorescence quenching of the excited } \ \textbf{PC-II} \ \ \text{with different concentrations of } \ \textbf{1a} \ \ \text{and } \ 2.0 \ \ \text{eq.} \ \ \text{K}_{3} \ \text{PO}_{4}$

Given that different concentrations of 1a and 1.0 eq. K_3PO_4 can't quench the excited **PC-II** photocatalyst, we try to increase the concentration of 1a and double the amount of K_3PO_4 . As shown in **Figure S4**, when the concentration of 1a and K_3PO_4 was increase to 6 mM and 10 mM, a slight quenching was obtained. Therefore, base on the previous works,^[12] we replaced K_3PO_4 with t-BuOK to increase the basicity so that favorably form potassium salt of 1a. As shown in **Figure S5**, obvious quenching was obtained. The result shows that the **PC-II** photocatalyst can be quenched by the potassium salt of 1a.




Figure S5 Fluorescence quenching of the excited PC-II with different concentrations of 1a and 1.0 eq. t-BuOK




Figure S6 Stern-Volmer emission quenching studies of the excited PC-II by 1a and 1.0 eq. t-BuOK




Figure S7 Fluorescence quenching of the excited PC-II with different concentrations of NFSI

However, as shown in **Figure S8**, the results of fluorescence quenching of the excited **PC-II** with different concentrations of DABSO suggest that the excited **PC-II** can also be quenched by DABSO. We think that after the release of sulfur dioxide, DABSO was converted to DABCO, so that the tertiary amine compounds can quench the excited **PC-II** photocatalyst. Therefore, as shown in **Figure S10**, we investigated the fluorescence quenching of excited **PC-II** with different concentrations of DABCO.




Figure S8 Fluorescence quenching of the excited PC-II with different concentrations of DABSO




Figure S9 Stern-Volmer emission quenching studies of the excited PC-II with DABSO




Figure S10 Fluorescence quenching of the excited PC-II with different concentrations of DABCO





Figure S11 Stern-Volmer emission quenching studies of PC-II by DABCO

9. Large-scale Experiment



To a 100 mL round-bottom flask equipped with a magnetic stirring bar, amide 1 (1 mmol, 1.0 eq.), DABSO (361 mg, 1.5 mmol, 1.5 eq.), NFSI (631 mg, 2 mmol, 2.0 eq.), $[Ir(dF(CF_3)ppy)_2(bpy)]PF_6$ (15 mg, 1.5 mol%), K_3PO_4 (213 mg, 1 mmol, 1.0 eq.), and MeCN (4.0 mL), were added successively under N_2 atmosphere. The reaction was carried out under the illumination of two 12 W blue lamps and the heat from light was blown away by fan. After stirring at room temperature for 10 h, the reaction mixture was filtered through a pad of celite, eluted with ethyl acetate, concentrated, and purified by flash column chromatography (eluent: petroleum ether/ ethyl acetate 5:1 to 3:1) on silica gel to give the desired product 2.

10. Characterization of Compounds 1d, 1e, 1I-1r, 1t-1ad, 1af-1ao, 2a-2ao, D1-D14, S5

Characterization of compounds 1a, 1b, 1c, 1f, 1g, 1h, 1i, 1j, 1k, 1s have been reported in the literature. [13] Characterization of compounds 1ae have been reported in the literature.

N-(4-bromophenyl)pent-4-enamide (1d)

Compound 1d was prepared according to Method A.

 1 H NMR (400 MHz, CDCl3) δ 7.55 (s, 1 H), 7.39 (s, 4H), 5.85 (ddd, J = 10.3, 7.8, 4.1 Hz, 1H), 5.20 – 4.97 (m, 2H), 2.45 (d, J = 8.2 Hz, 4H). 13 C NMR (101 MHz, CDCl3) δ 170.9, 137.0, 136.7, 132.0, 121.6, 116.9, 116.1, 36.8, 29.4. **HRMS (ESI):** m/z calculated for [M] (C_{11} H₁₂NOBr) from [M-H]* is 252.0029, found 252.0022.

N-(p-tolyl)pent-4-enamide (1e)

Compound 1e was prepared according to Method A.

¹H NMR (400 MHz, CDCl₃) δ 7.58 (s, $\tilde{1}$ H), 7.38 (d, J = 8.3 Hz, 2H), 7.09 (d, J = 8.2 Hz, 2H), 5.86 (dq, J = 10.5, 6.1 Hz, 1H), 5.07 (dd, J = 26.4, 13.5 Hz, 2H), 2.53 – 2.37 (m, 4H), 2.30 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 170.7, 137.0, 135.4, 133.9, 129.5, 120.2, 115.8, 36.7, 29.6, 20.9. **HRMS (ESI)**: m/z calculated for [M] ($C_{12}H_{15}NO$) from [M+Na]⁺ is 212.1046, found 212.1031.

ethyl 3-(pent-4-enamido)benzoate (11)

Compound 1I was prepared according to the Method A.

1H NMR (400 MHz, CDCl₃) δ 8.01 (s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.83 (s, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.36 (t, J = 7.9 Hz, 1H), 6.12 – 5.63 (m, 1H), 5.31 – 4.79 (m, 2H), 4.35 (q, J = 7.1 Hz, 2H), 2.47 (d, J = 2.7 Hz, 4H), 1.36 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl₃) δ 171.1, 166.4, 138.2, 136.8, 131.2, 129.2, 125.3, 124.5, 120.7, 116.0, 61.3, 36.7, 29.4, 14.3. **HRMS (ESI):** m/z calculated for [M] ($C_{14}H_{17}NO_3$) from [M+Na]⁺ is 270.1101, found 270.1090.

N-(3-methoxyphenyl)pent-4-enamide (1m)

Compound 1m was prepared according to Method A.

N-(3-(benzyloxy)phenyl)pent-4-enamide (1n)

Compound 1n was prepared according to Method A.

 $^{1}\text{H NMR } (400 \text{ MHz, CDCl3}) \ \delta \ 7.37 \ (\text{ddd}, \ J = 23.2, \ 13.1, \ 7.0 \ \text{Hz}, \ 7\text{H}), \ 7.19 \ (\text{t}, \ J = 8.1 \ \text{Hz}, \ 1\text{H}), \ 6.98 \ (\text{d}, \ J = 7.7 \ \text{Hz}, \ 1\text{H}), \ 6.73 \ (\text{d}, \ J = 7.7 \ \text{Hz}, \ 1\text{H}), \ 5.87 \ (\text{ddd}, \ J = 16.5, \ 10.4, \ 6.0 \ \text{Hz}, \ 1\text{H}), \ 5.28 \ - \ 4.86 \ (\text{m}, \ 4\text{H}), \ 2.46 \ (\text{dd}, \ J = 10.5, \ 5.1 \ \text{Hz}, \ 4\text{H}). \ ^{13}\text{C NMR} \ (101 \ \text{MHz, CDCl3}) \ \delta \ 170.7, \ 159.4, \ 139.2, \ 136.9 \ (\text{d}, \ J = 3.3 \ \text{Hz}), \ 129.8, \ 128.6, \ 128.0, \ 127.6, \ 116.0, \ 112.3, \ 111.1, \ 106.5, \ 70.0, \ 36.9, \ 29.5. \ \textbf{HRMS (ESI): m/z} \ \text{calculated for [M]} \ (C_{18}H_{19}NO_2) \ \text{from [M+Na]}^+ \ \text{is } 304.1308, \ \text{found } 304.1295.$

N-(3,4-dichlorophenyl)pent-4-enamide (1o)

Compound 10 was prepared according to Method A.

¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 1.9 Hz, 1H), 7.53 (s, 1H), 7.38 – 7.27 (m, 2H), 5.97 – 5.77 (m, 1H), 5.25 – 4.99 (m, 2H), 2.46 (d, J = 2.7 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 170.9, 137.3, 136.6, 132.8, 130.5, 127.5, 121.7, 119.2, 116.3, 36.7, 29.3. **HRMS (ESI):** m/z calculated for [M] ($C_{11}H_{11}Cl_2NO$) from [M+Na]⁺ is 266.0110, found 266.0093.

methyl 3-(pent-4-enamido)thiophene-2-carboxylate (1p)

Compound 1p was prepared according to Method A.

 1 H NMR (400 MHz, CDCl₃) δ 10.17 (s, 1H), 8.12 (d, J = 5.4 Hz, 1H), 7.45 (d, J = 5.4 Hz, 1H), 6.17 – 5.70 (m, 1H), 5.06 (dd, J = 30.3, 13.7 Hz, 2H), 3.88 (s, 3H), 2.99 – 2.29 (m, 4H). 13 C NMR (101 MHz, CDCl₃) δ 170.0, 164.9, 144.9, 136.5, 131.8, 122.4, 115.9, 109.9, 52.0, 36.8, 29.2. **HRMS (ESI)**: m/z calculated for [M] (C₁₁H₁₃NO₃S) from [M+Na]* is 262.0508, found 262.0505.

N-(6-methoxypyridin-3-yl)pent-4-enamide (1q)

Compound 1q was prepared according to Method A.

 1 H NMR (400 MHz, CDCl₃) δ 8.12 (d, J = 2.6 Hz, 1H), 7.83 (dd, J = 8.9, 2.7 Hz, 2H), 6.67 (d, J = 8.9 Hz, 1H), 6.18 – 5.57 (m, 1H), 5.04 (ddd, J = 13.7, 11.6, 1.5 Hz, 2H), 3.87 (s, 3H), 2.43 (d, J = 2.5 Hz, 4H). 13 C NMR (101 MHz, CDCl₃) δ 171.2, 161.0, 138.8, 136.7, 132.6, 128.6, 115.9, 110.4, 53.5, 36.2, 29.4. **HRMS (ESI)**: m/z calculated for [M] ($C_{11}H_{14}N_2O_2$) from [M+H]⁺ is 207.1128, found 207.1112.

N-(4-chlorophenyl)-2-methylpent-4-enamide (1r)

Compound 1r was prepared according to Method A.

 $^1\text{H NMR } (400 \text{ MHz, CDCl}_3) \ \delta \ 7.65 - 7.36 \ (\text{m}, \ 3\text{H}), \ 7.25 \ (\text{d}, \ J=9.0 \ \text{Hz}, \ 2\text{H}), \ 5.78 \ (\text{ddd}, \ J=13.8, \ 10.1, \ 6.9 \ \text{Hz}, \ 1\text{H}), \ 5.25 - 4.93 \ (\text{m}, \ 2\text{H}), \ 2.44 \ (\text{ddd}, \ J=14.0, \ 13.2, \ 6.9 \ \text{Hz}, \ 2\text{H}), \ 2.23 \ (\text{dd}, \ J=13.5, \ 6.3 \ \text{Hz}, \ 1\text{H}), \ 1.23 \ (\text{d}, \ J=6.7 \ \text{Hz}, \ 3\text{H}). \ ^{13}\text{C NMR } (101 \ \text{MHz, CDCl}_3) \ \delta \ 174.4, \ 136.5, \ 135.5, \ 129.3, \ 129.0, \ 121.4, \ 117.4, \ 42.2, \ 38.4, \ 17.5. \ \textbf{HRMS (ESI):} \ \text{m/z calculated for [M] } (C_{12}H_{14}\text{CINO}) \ \text{from [M+H]}^+ \ \text{is } 224.0837, \ \text{found } 224.0830.$

N-(4-chlorophenyl)-2-(p-tolyl)pent-4-enamide (1t)

Compound 1t was prepared according to Method A, starting from S2.

 1 H NMR (400 MHz, CDCl₃) δ 7.37 (d, J = 8.8 Hz, 2H), 7.21 (ddd, J = 17.6, 10.7, 5.1 Hz, 7H), 5.74 (ddt, J = 17.1, 10.1, 6.9 Hz, 1H), 5.04 (ddd, J = 13.6, 11.2, 1.2 Hz, 2H), 3.54 (t, J = 7.6 Hz, 1H), 2.97 (dt, J = 14.2, 7.0 Hz, 1H), 2.57 (dt, J = 14.6, 7.4 Hz, 1H), 2.35 (s, 3H). 13 C NMR (101 MHz, CDCl₃) δ 171.3, 137.5, 136.3, 135.7, 135.6, 129.8, 129.2, 128.9, 127.9, 121.0, 117.0, 53.6, 37.3, 21.1. **HRMS (ESI):** m/z calculated for [M] (C₁₈H₁₈CINO) from [M+Na]⁺ is 322.0969, found 322.0985.

2-benzyl-N-(4-chlorophenyl)pent-4-enamide (1u)

Compound 1u was prepared according to Method A, starting from S1.

 1 H NMR (400 MHz, CDCl₃) δ 7.32 – 7.14 (m, 9H), 6.91 (s, 1 H), 5.90 – 5.76 (m, 1H), 5.22 – 5.04 (m, 2H), 2.97 (dd, J = 13.5, 9.1 Hz, 1H), 2.86 (dd, J = 13.5, 5.0 Hz, 1H), 2.61 – 2.45 (m, 2H), 2.40 – 2.27 (m, 1H). 13 C NMR (101 MHz, CDCl₃) δ 172.8, 139.5, 136.0, 135.4, 129.4, 129.0, 128.9, 128.7, 126.7, 121.5, 117.6, 50.9, 38.9, 36.8. **HRMS (ESI)**: m/z calculated for [M] (C₁₈H₁₈CINO) from [M+Na]⁺ is 322.0969, found 322.0985.

N-(4-chlorophenyl)-2-(1,3-dioxoisoindolin-2-yl)pent-4-enamide (1v)


Compound 1v was prepared according to Method A.

 1 H NMR (400 MHz, CDCl₃) δ 8.49 (s, 1 H), 7.89 – 7.81 (m, 2H), 7.79 – 7.71 (m, 2H), 7.44 (d, J = 8.7 Hz, 2H), 7.23 (d, J = 8.8 Hz, 2H), 6.03 – 5.59 (m, 1H), 5.31 – 4.76 (m, 3H), 3.20 – 2.91 (m, 2H). 13 C NMR (101 MHz, CDCl₃) δ 168.3, 166.7, 136.0, 134.5, 133.0, 131.4, 129.6, 128.9, 123.7, 121.3, 119.6, 55.3, 33.7. **HRMS (ESI)**: m/z calculated for [M] ($C_{19}H_{15}CIN_2O_3$) from [M+H]⁺ is 355.0844, found 355.0853.

tert-butyl (1-((4-chlorophenyl)amino)-1-oxopent-4-en-2-yl)carbamate (1w)

Compound 1w was prepared according to Method A.

 1 H NMR (400 MHz, CDCl₃) δ 8.91 (s, 1 H), 7.37 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 5.80 (td, J = 16.9, 7.2 Hz, 1H), 5.35 (s, 1H), 5.16 (t, J = 12.9 Hz, 2H), 4.37 (s, 1H), 2.85 – 2.39 (m, 2H), 1.43 (s, 9H). 13 C NMR (101 MHz, CDCl₃) δ 170.3, 156.4, 136.4, 132.9, 129.2, 128.9, 121.1, 119.3, 80.9, 54.7, 36.5, 28.4. **HRMS (ESI):** m/z calculated for [M] ($C_{16}H_{21}CIN_2O_3$) from [M+Na]⁺ is 347.1133, found 347.1145.



(9H-fluoren-9-yl)methyl ®-(1-((4-chlorophenyl)amino)-1-oxopent-4-en-2-yl)carbamate (1x)

Compound 1x was prepared according to Method A.

¹H NMR (400 MHz, DMSO- d_6) δ 10.21 (s, 1H), 7.88 (d, J = 7.4 Hz, 2H), 7.73 (d, J = 7.5 Hz, 3H), 7.64 (d, J = 8.6 Hz, 2H), 7.47 – 7.28 (m, 6H), 5.90 – 5.72 (m, 1H), 5.10 (dd, J = 30.6, 13.6 Hz, 2H), 4.38 – 4.13 (m, 4H), 2.48 – 2.33 (m, 2H). ¹³C NMR (101 MHz, DMSO- d_6) δ 170.5, 156.0, 143.8, 143.7, 140.7, 137.7, 134.0, 128.6, 127.6, 127.0, 125.3, 120.8, 120.1, 117.7, 65.7, 55.0, 46.6, 36.0. **HRMS** (ESI): m/z calculated for [M] ($C_{26}H_{23}CIN_2O_3$) from [M+Na]⁺ is 469.1289, found 469.1320.

$$\bigcup_{C|} \bigcup_{N} \bigcup_{O} \bigcup_{O}$$

(E)-6-(benzyloxy)-N-(4-chlorophenyl)hex-4-enamide (1y)

Compound 1y was prepared according to Method C.

 1 H NMR (400 MHz, CDCl₃) δ 7.69 (d, J = 25.3 Hz, 1H), 7.43 (dd, J = 14.1, 8.8 Hz, 2H), 7.37 – 7.19 (m, 7H), 5.87 – 5.51 (m, 2H), 4.50 (d, J = 6.9 Hz, 2H), 4.04 (dd, J = 50.0, 6.0 Hz, 2H), 2.53 – 2.35 (m, 4H). 13 C NMR (101 MHz, CDCl₃) δ 170.7, 138.0, 136.5, 131.9, 129.2, 128.9, 128.5, 128.0, 127.9, 127.7, 121.3, 72.6, 65.7, 37.1, 23.5. **HRMS (ESI):** m/z calculated for [M] (C₁₉H₂₀ClNO₂) from [M+Na]⁺ is 352.1075, found 352.1093.

N-(4-chlorophenyl)cyclohex-3-ene-1-carboxamide (1z)

Compound 1z was prepared according to Method C.

 1 H NMR (400 MHz, CDCl₃) δ 7.42 (t, J = 12.9 Hz, 2H), 7.33 - 7.13 (m, 8H), 5.68 - 5.30 (m, 2H), 2.82 - 2.59 (m, 2H), 2.50 - 2.08 (m, 6H). 13 C NMR (101 MHz, CDCl₃) δ 170.9, 142.0, 136.5, 130.7, 129.0, 128.8, 128.5, 128.4, 128.3, 125.9, 121.1, 37.5, 35.8, 29.2, 23.3. **HRMS (ESI):** m/z calculated for [M] ($C_{19}H_{20}$ CINO) from [M+Na]⁺ is 336.1126, found 336.1127.

N-(4-chlorophenyl)cyclohex-3-ene-1-carboxamide (1aa)

Compound 1aa was prepared according to Method~A.

 1 H NMR (400 MHz, DMSO- $^{\prime}$ d₆) δ 10.02 (s, 1H), 7.64 (d, J = 8.8 Hz, 2H), 7.49 – 7.19 (m, 2H), 6.30 – 5.11 (m, 2H), 2.61 – 2.51 (m, 1H), 2.30 – 1.98 (m, 4H), 1.88 (d, J = 12.1 Hz, 1H), 1.56 (dt, J = 12.3, 10.1 Hz, 1H). 13 C NMR (101 MHz, DMSO- $^{\prime}$ d₆) δ 165.9, 131.9, 131.6, 124.5, 124.2, 116.3, 111.3, 32.0, 28.3, 24.6, 23.8. **HRMS (ESI):** m/z calculated for [M] (C₁₃H₁₄CINO) from [M+Na]⁺ is 258.0656, found 258.0637.

N-(4-chlorophenyl)-2-(cyclopent-2-en-1-yl)acetamide (1ab)

Compound 1ab was prepared according to Method A.

¹H NMR (400 MHz, DMSO- d_6) δ 10.01 (s, 1H), 7.62 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 8.8 Hz, 2H), 5.73 (ddd, J = 22.7, 5.6, 2.2 Hz, 2H), 3.18 – 2.83 (m, 1H), 2.44 – 2.18 (m, 4H), 2.11 – 1.94 (m, 1H), 1.46 (ddt, J = 12.6, 9.0, 6.2 Hz, 1H). ¹³C NMR (101 MHz, DMSO- d_6) δ 170.5, 138.1, 134.3, 130.7, 128.5, 126.5, 120.5, 42.4, 42.1, 31.4, 29.0. **HRMS (ESI)**: m/z calculated for [M] (C1₃H₁₄CINO) from [M+Na]⁺ is 258.0656, found 258.0638.

2-methoxybenzene-1-sulfonyl fluoride (1ac)

Compound 1ac was prepared according to Method~B.

 1 H NMR (400 MHz, DMSO- d_{6}) δ 9.86 (s, 1H), 7.59 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H), 6.15 (dd, J = 5.5, 3.0 Hz, 1H), 5.83 (dd, J = 5.5, 2.7 Hz, 1H), 3.27 (s, 1H), 3.09 – 2.97 (m, 1H), 2.86 (s, 1H), 1.80 (ddd, J = 12.6, 9.3, 3.7 Hz, 1H), 1.48 – 1.26 (m, 3H). 13 C NMR (101 MHz, DMSO- d_{6}) δ 172.0, 138.4, 137.2, 131.6, 128.4, 126.1, 120.5, 49.5, 46.1, 44.2, 42.2, 28.2. **HRMS (ESI):** m/z calculated for [M] (C_{14} H₁₄CINO) from [M+Na]* is 270.0656, found 270.0641.

N-(4-chlorophenyl)cyclopent-3-ene-1-carboxamide (1ad)

Compound 1ad was prepared according to Method A.

 1 H NMR (400 MHz, DMSO- $^{\prime}d_{6}$) δ 10.05 (s, 1H), 7.64 (d, J = 8.9 Hz, 2H), 7.34 (d, J = 8.9 Hz, 2H), 5.66 (s, 2H), 3.26 – 3.09 (m, 1H), 2.67 – 2.51 (m, 4H). 13 C NMR (101 MHz, DMSO- $^{\prime}d_{6}$) δ 174.0, 138.3, 129.0, 128.5, 126.5, 120.6, 42.9, 36.6. **HRMS (ESI)**: m/z calculated for [M] ($^{\prime}C_{12}$ H₁₂CINO) from [M+Na]* is 244.0500, found 244.0492.

2-methylallyl (4-chlorophenyl)carbamate (1af)

Compound 1af was prepared according to Method B.

 1 H NMR (400 MHz, CDCl₃) δ 7.34 (d, J = 8.6 Hz, 2H), 7.26 (d, J = 8.9 Hz, 2H), 6.77 (s, 1H), 4.98 (d, J = 24.5 Hz, 2H), 4.58 (s, 2H), 1.78 (s, 3H). 13 C NMR (101 MHz, CDCl₃) δ 153.3, 140.1, 136.5, 129.1, 128.6, 120.0, 113.1, 68.7, 19.5. **HRMS (ESI):** m/z calculated for [M] (C_{11} H₁₂CINO₂) from [M+Na]⁺ is 248.0449, found 248.0435.

pent-1-en-3-yl (4-chlorophenyl)carbamate (1ag)

Compound 1ag was prepared according to Method B.

¹H NMR (400 MHz, CDCl₃) δ 7.34 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 8.9 Hz, 2H), 6.71 (s, 1H), 5.81 (ddd, J = 17.1, 10.5, 6.5 Hz, 1H), 5.26 (ddt, J = 31.9, 10.5, 1.2 Hz, 2H), 5.16 (q, J = 6.5 Hz, 1H), 1.78 – 1.63 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 153.0, 136.7, 136.4, 129.1, 128.4, 119.9, 117.1, 27.4, 9.5. **HRMS (ESI)**: m/z calculated for [M] (C₁₂H₁₄CINO₂) from [M+Na]+ is 262.0605, found 262.0588.

(E)-but-2-en-1-yl (4-chlorophenyl)carbamate (1ah)

Compound 1ah was prepared according to Method B.

 1 H NMR (400 MHz, CDCl₃) δ 7.34 (d, J = 8.7 Hz, 2H), 7.27 (d, J = 8.8 Hz, 2H), 6.68 (s, 1H), 5.85 (dq, J = 13.0, 6.5 Hz, 1H), 5.72 – 5.56 (m, 1H), 4.60 (d, J = 6.5 Hz, 2H), 1.82 – 1.70 (m, 3H). 13 C NMR (101 MHz, CDCl₃) δ 153.4, 136.6, 131.9, 129.1, 128.5, 125.2, 120.0, 66.2, 17.9. **HRMS (ESI):** m/z calculated for [M] (C₁₁H₁₂CINO₂) from [M+Na]* is 248.0449, found 248.0443.

$$H \rightarrow 0$$

(E)-hex-2-en-1-yl (4-chlorophenyl)carbamate (1ai)

Compound 1ai was prepared according to Method B.

 1 H NMR (400 MHz, CDCl₃) δ 7.34 (d, J = 8.8 Hz, 2H), 7.29 – 7.25 (m, 2H), 6.68 (s, 2H), 5.92 – 5.75 (m, 1H), 5.62 (dddd, J = 13.1, 7.9, 4.6, 3.2 Hz, 1H), 4.61 (dd, J = 6.5, 0.7 Hz, 2H), 2.06 (q, J = 7.1 Hz, 2H), 1.55 – 1.28 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 13 C NMR (101 MHz, CDCl₃) δ 153.4, 136.9, 136.6, 129.1, 124.0, 119.9, 66.3, 34.4, 22.1, 13.7. **HRMS (ESI):** m/z calculated for [M] (C₁₃H₁₆CINO₂) from [M+Na]⁺ is 276.0762, found 276.0759.

cyclohex-2-en-1-yl (4-chlorophenyl)carbamate (1aj)

Compound 1aj was prepared according to Method B.

 1 H NMR (400 MHz, CDCl₃) δ 7.33 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 8.9 Hz, 2H), 6.65 (s, 1H), 6.10 – 5.92 (m, 1H), 5.85 – 5.69 (m, 1H), 5.27 (dd, J = 3.4, 1.5 Hz, 1H), 2.17 – 1.64 (m, 6H). 13 C NMR (101 MHz, CDCl₃) δ 153.2, 136.7, 133.1, 129.1, 128.3, 125.7, 119.9, 69.2, 28.6, 25.0, 18.8. **HRMS (ESI):** m/z calculated for [M] (C_{13} H₁₄ClNO₂) from [M+Na]⁺ is 274.0605, found 274.0601.

1-allyl-3-(4-chlorophenyl)-1-phenylurea (1ak)

Compound 1ak was prepared according to Method B.

 1 H NMR (400 MHz, CDCl₃) δ 7.52 – 7.44 (m, 2H), 7.42 – 7.36 (m, 1H), 7.33 – 7.28 (m, 2H), 7.26 – 7.15 (m, 2H), 6.18 (s, 1H), 6.04 – 5.84 (m, 1H), 5.22 – 5.03 (m, 2H), 4.33 (dt, J = 6.2, 1.3 Hz, 2H). 13 C NMR (101 MHz, CDCl₃) δ 153.8, 141.2, 137.5, 133.9, 130.4, 128.8, 128.6, 128.4, 127.9, 120.5, 117.7, 52.4. **HRMS (ESI):** m/z calculated for [M] (C₁₆H₁₅ClN₂O) from [M+H]* is 287.0946, found 287.0942

N-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenyl)pent-4-enamide (1al)


Compound 1al was prepared according to Method A.

¹H NMR (400 MHz, DMSO- d_6) δ 11.59 (s, 1H), 10.26 (s, 1H), 7.93 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 6.73 (s, 1H), 5.83 (dd, J = 16.3, 9.6 Hz, 1H), 5.01 (dd, J = 42.7, 13.5 Hz, 2H), 2.43 (d, J = 6.8 Hz, 2H), 2.33 (d, J = 5.9 Hz, 2H), 2.24 (s, 6H). ¹³C NMR (101 MHz, DMSO- d_6) δ 171.1, 167.3, 156.2, 142.8, 137.4, 134.2, 129.3, 117.9, 115.3, 113.6, 35.5, 28.8, 22.9. **HRMS (ESI):** m/z calculated for [M] ($C_{17}H_{20}N4O_3S$) from [M+H]* is 361.1329, found 361.1348.

N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-enamide (1am)

Compound 1am was prepared according to Method A.

 1 H NMR (400 MHz, CDCl₃) δ 7.77 (s, 1H), 7.30 (s, 1H), 7.17 (t, J = 8.1 Hz, 1H), 6.98 (d, J = 7.9 Hz, 1H), 6.72 – 6.57 (m, 1H), 5.84 (ddd, J = 15.9, 8.6, 4.9 Hz, 1H), 5.05 (dd, J = 25.6, 13.7 Hz, 2H), 3.75 (s, 3H), 2.44 (s, 4H). 13 C NMR (101 MHz, CDCl₃) δ 172.9, 171.1, 170.6, 167.8, 137.5, 133.8, 133.7, 132.6, 128.6, 125.2, 119.0, 115.3, 51.5, 46.5, 34.9, 31.2, 29.1, 22.6. **HRMS (ESI)**: m/z calculated for [M] ($C_{18}H_{19}N_{3}O_{4}$) from [M+H]† is 342.1448, found 342.1458.



(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 4-(pent-4-enamido)benzoate (1an)

Compound 1an was prepared according to Method A.

 1 H NMR (400 MHz, CDCl₃) δ 8.65 (s, 1H), 7.96 (d, J = 8.7 Hz, 2H), 7.65 (d, J = 8.6 Hz, 2H), 5.80 (tt, J = 16.4, 6.2 Hz, 1H), 5.01 (ddd, J = 13.7, 11.5, 1.3 Hz, 2H), 4.88 (td, J = 10.8, 4.3 Hz, 1H), 2.46 (ddd, J = 12.5, 6.9, 3.6 Hz, 4H), 2.07 (d, J = 11.9 Hz, 1H), 2.00 – 1.83 (m, 1H), 1.80 – 1.63 (m, 2H), 1.51 (ddd, J = 19.8, 14.5, 5.7 Hz, 2H), 1.08 (dd, J = 23.3, 12.0 Hz, 2H), 0.89 (d, J = 6.8 Hz, 7H), 0.75 (d, J = 6.9 Hz, 3H). 13 C NMR (101 MHz, CDCl₃) δ 171.6, 166.0, 142.4, 136.6, 130.7, 125.9, 119.0, 115.8, 74.9, 47.2, 41.0, 36.7, 34.2, 31.4, 29.3, 26.5, 23.7, 22.0, 20.7, 16.6. **HRMS (ESI):** m/z calculated for [M] ($C_{22}H_{31}NO_3$) from [M+Na]⁺ is 380.2196, found 380.2192.

(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(pent-4-enamido) benzoate (1ao)

Compound 1ao was prepared according to Method A.

 $^{1}\text{H NMR } (400 \text{ MHz, $CDCl}_{3}) \ \delta \ 8.12 \ (d, \ J=8.7 \ \text{Hz, } 2\text{H}), \ 7.90 \ (s, \ 1\text{H}), \ 7.65 \ (d, \ J=8.7 \ \text{Hz, } 2\text{H}), \ 7.31 \ (d, \ J=8.5 \ \text{Hz, } 1\text{H}), \ 7.07 - 6.85 \ (m, \ 2\text{H}), \ 6.00 - 5.75 \ (m, \ 1\text{H}), \ 5.22 - 4.99 \ (m, \ 2\text{H}), \ 3.02 - 2.83 \ (m, \ 2\text{H}), \ 2.62 - 1.93 \ (m, \ 12\text{H}), \ 1.74 - 1.39 \ (m, \ 5\text{H}), \ 0.92 \ (s, \ 3\text{H}), \ ^{13}\text{C NMR} \ (101 \ \text{MHz, } \text{CDCl}_{3}) \ \delta \ 171.1, \ 165.2, \ 148.9, \ 142.9, \ 138.2, \ 137.5, \ 136.7, \ 131.5, \ 126.5, \ 124.7, \ 121.8, \ 118.9, \ 118.9, \ 116.1, \ 50.5, \ 48.1, \ 44.2, \ 38.0, \ 36.9, \ 36.0, \ 31.6, \ 29.5, \ 29.3, \ 26.4, \ 25.8, \ 21.6, \ 13.9. \ \textbf{HRMS } \textbf{(ESI):} \ \text{m/z calculated for } [\text{M}] \ (\text{C}_{30}\text{H}_{33}\text{NO}_{4}) \ \text{from } [\text{M}+\text{H}]^+ \ \text{is } 472.2482, \ \text{found } 472.2514.$

(5-oxo-1-phenylpyrrolidin-2-yl)methanesulfonyl fluoride (2a)

Compound **2a** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (15.4 mg, 60% yield).

¹H NMR (400 MHz, CDCl3) δ 7.44 (dt, J = 9.2, 1.9 Hz, 2H), 7.40 – 7.34 (m, 2H), 7.32 – 7.26 (m, 1H), 4.88 – 4.62 (m, 1H), 3.67 (ddd, J = 14.6, 4.5, 2.3 Hz, 1H), 3.40 (ddd, J = 14.6, 10.0, 3.0 Hz, 1H), 2.83 – 2.52 (m, 3H), 2.36 – 2.17 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 173.5, 135.8, 129.8, 127.1, 123.8, 54.9, 53.1 (d, J = 14.8 Hz), 30.3, 23.8. ¹⁹F NMR (376 MHz, CDCl₃) δ 60.51. **HRMS (ESI)**: m/z calculated for [M] (C₁₁H₁₂FNO₃S) from [M+H]⁺ is 258.0595, found 258.0603

(1-(4-fluorophenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2b)

Compound **2b** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (15.4 mg, 56% yield).

¹H NMR (400 MHz, $\dot{\text{CDCl}_3}$) δ 7.40 – 7.28 (m, 2H), 7.20 – 7.08 (m, 2H), 4.79 – 4.60 (m, 1H), 3.64 (ddd, J = 14.6, 4.3, 2.4 Hz, 1H), 3.41 (ddd, J = 14.6, 9.8, 2.8 Hz, 1H), 2.76 – 2.54 (m, 3H), 2.34 – 2.19 (m, 1H). ¹³C NMR (101 MHz, $\dot{\text{CDCl}_3}$) δ 173.5, 161.1 (d, J = 247.9 Hz), 131.8 (d, J = 3.0 Hz), 125.9 (d, J = 8.5 Hz), 116.8 (d, J = 22.8 Hz), 55.2, 53.1 (d, J = 14.9 Hz), 30.1, 23.9. ¹⁹F NMR (376 MHz, $\dot{\text{CDCl}_3}$) δ 60.78, -113.72. **HRMS (ESI):** m/z calculated for [M] ($\dot{\text{C}_{11}}\dot{\text{H}_{11}}\dot{\text{F}_{2}}\dot{\text{NO}_{3}}\dot{\text{S}}$) from [M+H]⁺ is 276.0500, found 276.0495

(1-(4-chlorophenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2c)

Compound **2c** was prepared according to the **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (22.7 mg, 78% yield).

 1 H NMR (400 MHz, CDCl₃) δ 7.45 – 7.39 (m, 2H), 7.39 – 7.33 (m, 2H), 4.95 – 4.65 (m, 1H), 3.66 (ddd, J = 14.6, 4.3, 2.3 Hz, 1H), 3.41 (ddd, J = 14.6, 9.8, 2.7 Hz, 1H), 2.81 – 2.58 (m, 3H), 2.39 – 2.20 (m, 1H). 13 C NMR (101 MHz, CDCl₃) δ 173.4, 134.4, 132.5, 130.0, 124.7, 54.7, 53.0 (d, J = 14.9 Hz), 30.2, 23.8. 19 F NMR (376 MHz, CDCl₃) δ 60.75. **HRMS (ESI)**: m/z calculated for [M] ($C_{11}H_{11}NO_3FSCI$) from [M+H]† is 292.0205, found 292.0201

(1-(4-bromophenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2d)

Compound **2d** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (24.1 mg, 72% yield).

¹H NMR (400 MHz, $\dot{C}DCl_3$) δ 7.63 – 7.47 (m, 2H), 7.34 – 7.17 (m, 2H), 4.81 – 4.71 (m, 1H), 3.65 (ddd, J = 14.6, 4.3, 2.3 Hz, 1H), 3.42 (ddd, J = 14.6, 9.8, 2.7 Hz, 1H), 2.83 – 2.51 (m, 3H), 2.34 – 2.19 (m, 1H). ¹³C NMR (126 MHz, $\dot{C}DCl_3$) δ 173.3, 134.9, 132.9, 124.9, 120.3, 54.6, 53.0 (d, J = 15.0 Hz), 30.2, 23.7. ¹⁹F NMR (376 MHz, $\dot{C}DCl_3$) δ 60.72. **HRMS (ESI):** m/z calculated for [M] ($\dot{C}_{11}H_{11}NO_3FSBr$) from [M+H]⁺ is 335.9700, found 335.9706

(5-oxo-1-(p-tolyl)pyrrolidin-2-yl)methanesulfonyl fluoride (2e)

Compound **2e** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (11.4 mg, 42% yield).

 1 H NMR (400 MHz, CDCl₃) δ 7.28 – 7.15 (m, 4H), 4.82 – 4.62 (m, 1H), 3.66 (ddd, J = 14.6, 4.5, 2.4 Hz, 1H), 3.38 (ddd, J = 14.6, 10.0, 3.1 Hz, 1H), 2.74 – 2.56 (m, 3H), 2.35 (s, 3H), 2.28 – 2.17 (m, 1H). 13 C NMR (101 MHz, CDCl₃) δ 173.5, 137.2, 133.1, 130.4, 124.0, 55.1, 53.2 (d, J = 14.6 Hz), 30.2, 23.9, 21.1. 19 F NMR (376 MHz, CDCl₃) δ 60.47. **HRMS (ESI)**: m/z calculated for [M] (C₁₂H₁₄NO₃FS) from [M+H]* is 272.0751, found 272.0739

(1-(4-acetylphenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2f)

Compound **2f** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 3:1 to 1:1) to give a white solid (15.0 mg, 50% yield).

¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 8.6 Hz, 2H), 7.58 (d, J = 8.6 Hz, 2H), 4.90 (ddd, J = 9.8, 6.1, 4.0 Hz, 1H), 3.69 (ddd, J = 14.7, 4.0, 2.1 Hz, 1H), 3.47 (ddd, J = 14.6, 9.8, 2.6 Hz, 1H), 2.84 – 2.62 (m, 3H), 2.60 (s, 3H), 2.38 – 2.25 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 196.8, 173.4, 140.2, 134.7, 130.0, 122.0, 54.2, 52.8 (d, J = 15.1 Hz), 30.4, 26.7, 23.6. ¹⁹F NMR (376 MHz, CDCl₃) δ 60.61. **HRMS (ESI)**: m/z calculated for [M] ($C_{13}H_{14}NO_4FS$) from [M+H]⁺ is 322.0520, found 322.0517

(5-oxo-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-yl)methanesulfonyl fluoride (2g)

Compound **2g** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (8.1 mg, 25% yield).

 1 H NMR (500 MHz, CDCl₃) δ 7.71 (d, $^{\prime}$ J = 8.5 Hz, 2H), 7.60 (d, $^{\prime}$ J = 8.4 Hz, 2H), 4.88 (s, 1H), 3.68 (d, $^{\prime}$ J = 14.7 Hz, 1H), 3.56 – 3.36 (m, 1H), 2.91 – 2.56 (m, 3H), 2.32 (ddd, $^{\prime}$ J = 12.7, 7.2, 3.6 Hz, 1H). 13 C NMR (101 MHz, CDCl₃) δ 173.5, 139.1, 128.4 (d, $^{\prime}$ J = 33.1 Hz), 127.0 (dd, $^{\prime}$ J = 7.2, 3.6 Hz), 125.1, 122.6, 54.3, 52.8 (d, $^{\prime}$ J = 15.1 Hz), 30.3, 23.7. 19 F NMR (376 MHz, CDCl₃) δ 60.70 (s), -62.56 (s). **HRMS (ESI):** m/z calculated for [M] (C₁₂H₁₁NO₃F₄S) from [M+H]⁺ is 326.0469, found 326.0468

ethyl 4-(2-((fluorosulfonyl)methyl)-5-oxopyrrolidin-1-yl)benzoate (2h)

Compound **2h** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1 to 3:1) to give a white solid (18.4 mg, 56% yield).

¹H NMR (400 MHz, $\dot{\text{CDCl}_3}$) δ 8.10 (d, J = 8.5 Hz, 2H), 7.54 (d, J = 8.6 Hz, 2H), 4.87 (d, J = 2.9 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 3.77 – 3.59 (m, 1H), 3.57 – 3.36 (m, 1H), 2.85 – 2.45 (m, 3H), 2.42 – 2.05 (m, 1H), 1.38 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, $\dot{\text{CDCl}_3}$) δ 173.4, 165.7, 140.0, 131.1, 128.2, 121.9, 61.2, 54.3, 52.7 (d, J = 15.0 Hz), 30.4, 23.6, 14.4. ¹⁹F NMR (376 MHz, $\dot{\text{CDCl}_3}$) δ 60.52. **HRMS (ESI):** m/z calculated for [M] ($\dot{\text{C}_{14}}\dot{\text{H}_{16}}\dot{\text{NO}_5}FS$) from [M+H]⁺ is 352.0625, found 352.0609

4-(2-((fluorosulfonyl)methyl)-5-oxopyrrolidin-1-yl)benzoic acid (2i)

Compound **2i** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 3:1 to 1:1) to give a white solid (12.6 mg, 42% yield).

¹H NMR (400 MHz, ĎMSO- d_6) δ 12.90 (s, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H), 5.03 (t, J = 7.9 Hz, 1H), 4.38 (ddd, J = 14.1, 8.6, 5.2 Hz, 1H), 4.12 (ddd, J = 15.1, 5.0, 2.5 Hz, 1H), 2.77 (dt, J = 15.3, 7.9 Hz, 1H), 2.59 – 2.39 (m, 2H), 2.25 – 2.07 (m, 1H). ¹³C NMR (101 MHz, DMSO- d_6) δ 173.8, 166.8, 140.7, 130.2, 127.2, 122.0, 53.8, 51.6 (d, J = 11.7 Hz), 30.1, 22.7. ¹⁹F NMR (376 MHz, DMSO- d_6) δ 60.51. **HRMS (ESI)**: m/z calculated for [M] (C_{12} H₁₂NO₅FS) from [M+H]⁺ is 300.0347, found 300.0345

(1-(2-fluorophenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2j)

Compound **2j** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (17.6 mg, 64% yield).

¹H NMR (400 MHz, CDCl₃) δ 7.46 – 7.36 (m, 1H), 7.36 – 7.19 (m, 3H), 4.67 (ddd, J = 9.6, 5.1, 2.4 Hz, 1H), 3.61 – 3.36 (m, 2H), 2.82 – 2.53 (m, 3H), 2.39 – 2.25 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 174.0, 157.9 (d, J = 249.4 Hz), 130.4 (d, J = 6.7 Hz), 129.6, 125.3,

123.2, 117.2 (d, J = 20.0 Hz), 55.5, 53.5 (d, J = 14.8 Hz), 29.4, 24.7. ¹⁹F NMR (376 MHz, CDCl₃) δ 60.94, -119.82. **HRMS (ESI):** m/z calculated for [M] ($C_{11}H_{11}NO_3F_2S$) from [M+H]⁺ is 276.0500, found 276.0490

(1-(3-fluorophenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2k)

Compound **2k** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (17.0 mg, 62% yield).

¹H NMR (400 MHz, $\dot{\text{CDCl}_3}$) δ 7.40 (td, J = 8.2, 6.5 Hz, 1H), 7.31 (dt, J = 10.4, 2.2 Hz, 1H), 7.12 (dd, J = 8.1, 1.4 Hz, 1H), 6.98 (td, J = 8.2, 1.8 Hz, 1H), 4.78 (ddd, J = 9.8, 4.9, 2.5 Hz, 1H), 3.69 (ddd, J = 14.7, 4.3, 2.2 Hz, 1H), 3.44 (ddd, J = 14.6, 9.8, 2.9 Hz, 1H), 2.83 – 2.54 (m, 3H), 2.35 – 2.14 (m, 1H). ¹³C NMR (101 MHz, $\dot{\text{CDCl}_3}$) δ 173.4, 163.2 (d, J = 247.6 Hz), 137.5 (d, J = 10.1 Hz), 131.0 (d, J = 9.2 Hz), 118.0 (d, J = 3.1 Hz), 113.7 (d, J = 21.2 Hz), 110.9 (d, J = 25.0 Hz), 54.6, 52.8 (d, J = 14.9 Hz), 30.3, 23.6. ¹⁹F NMR (376 MHz, $\dot{\text{CDCl}_3}$) δ 60.57, -109.75. **HRMS (ESI):** m/z calculated for [M] ($\dot{\text{C}_{11}}\dot{\text{H}_{11}}\dot{\text{NO}_3}\dot{\text{F}_2}\dot{\text{S}}$) from [M+H]⁺ is 276.0500, found 276.0500

$$\mathsf{EtO_2C} \bigvee_{\mathsf{O}}^{\mathsf{SO_2F}} \mathsf{N} \bigvee_{\mathsf{O}}$$

ethyl 3-(2-((fluorosulfonyl)methyl)-5-oxopyrrolidin-1-yl)benzoate (21)

Compound **2I** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1 to 3:1) to give a white solid (20.4 mg, 62% yield).

¹H NMR (400 MHz, CDCl₃) δ 8.02 – 7.80 (m, 2H), 7.68 (ddd, J = 8.0, 2.1, 1.0 Hz, 1H), 7.52 (t, J = 7.9 Hz, 1H), 4.84 (ddd, J = 9.4, 5.8, 2.4 Hz, 1H), 4.49 – 4.27 (m, 2H), 3.66 (ddd, J = 14.7, 4.0, 2.4 Hz, 1H), 3.45 (ddd, J = 14.6, 9.7, 3.3 Hz, 1H), 2.87 – 2.52 (m, 3H), 2.39 – 2.20 (m, 1H), 1.39 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 173.5, 165.7, 136.2, 132.2, 129.9, 128.3, 128.0, 124.2, 61.5, 54.8, 53.0 (d, J = 14.9 Hz), 30.2, 23.8, 14.3. ¹⁹F NMR (376 MHz, CDCl₃) δ 60.73. **HRMS (ESI)**: m/z calculated for [M] (C₁₄H₁₆NO₅FS) from [M+H]⁺ is 352.0625, found 352.0608

$$\begin{array}{c} \text{SO}_2 \text{F} \\ \text{MeO} \\ \text{O} \end{array}$$

(1-(3-methoxyphenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2m)

Compound **2m** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1 to 3:1) to give a colourless oil (10.1 mg, 35% yield).

¹H NMR (400 MHz, $\dot{C}DCl_3$) δ 7.34 (t, J = 8.2 Hz, 1H), 7.01 (t, J = 2.2 Hz, 1H), 6.91 (dd, J = 7.9, 1.8 Hz, 1H), 6.82 (dd, J = 8.3, 2.4 Hz, 1H), 4.86 – 4.61 (m, 1H), 3.81 (s, 3H), 3.71 (ddd, J = 14.6, 4.5, 2.2 Hz, 1H), 3.50 – 3.32 (m, 1H), 2.79 – 2.56 (m, 3H), 2.33 – 2.17 (m, 1H). ¹³C NMR (101 MHz, $\dot{C}DCl_3$) δ 173.4, 160.7, 137.0, 130.5, 115.4, 112.7, 109.8, 55.5, 55.0, 53.1 (d, J = 14.7 Hz), 30.4, 23.8. ¹⁹F NMR (376 MHz, $\dot{C}DCl_3$) δ 60.44. **HRMS (ESI):** m/z calculated for [M] ($\dot{C}_{12}H_{14}NO_4FS$) from [M+H]* is 310.0520, found 310.0506

(1-(3-(benzyloxy)phenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2n)

Compound **2n** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1 to 3:1) to give a colourless oil (12.3 mg, 34% yield).

 1 H NMR (400 MHz, CDCl₃) δ 7.47 – 7.28 (m, 6H), 7.10 (t, J = 2.2 Hz, 1H), 6.91 (td, J = 8.1, 2.2 Hz, 2H), 5.12 – 5.03 (m, 2H), 4.82 – 4.58 (m, 1H), 3.69 (ddd, J = 14.6, 4.5, 2.3 Hz, 1H), 3.37 (ddd, J = 14.5, 10.0, 2.8 Hz, 1H), 2.84 – 2.53 (m, 3H), 2.35 – 2.18 (m, 1H). 13 C NMR (101 MHz, CDCl₃) δ 173.4, 159.8, 137.0, 136.5, 130.6, 128.7, 128.3, 127.6, 115.7, 113.6, 110.7, 70.3, 55.0, 53.1 (d, J = 14.7 Hz), 30.4, 23.8. 19 F NMR (376 MHz, CDCl₃) δ 60.61. **HRMS (ESI)**: m/z calculated for [M] (C₁₈H₁₈NO₄FS) from [M+H]⁺ is 386.0833, found 386.0816

(1-(3,4-dichlorophenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2o)

Compound **20** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1 to 3:1) to give a white solid (20.2 mg, 62% yield).

1H NMR (400 MHz, CDCL) & 7.64 (d. /= 2.4 Hz, 1H), 7.51 (d. /= 8.7 Hz, 1H), 7.24 (dd. /= 8.8, 2.5 Hz, 1H), 4.86 – 4.64 (m. 1H).

¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J = 2.4 Hz, 1H), 7.51 (d, J = 8.7 Hz, 1H), 7.24 (dd, J = 8.8, 2.5 Hz, 1H), 4.86 – 4.64 (m, 1H), 3.73 – 3.57 (m, 1H), 3.45 (ddd, J = 14.4, 9.6, 2.4 Hz, 1H), 2.88 – 2.51 (m, 3H), 2.46 – 2.15 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 173.3, 135.4, 133.8, 131.3, 130.7, 125.2, 122.0, 54.5, 52.8 (d, J = 15.1 Hz), 30.1, 23.6. ¹⁹F NMR (376 MHz, CDCl₃) δ 60.89. **HRMS** (ESI): m/z calculated for [M] (C₁₁H₁₀NO₃FSCl₂) from [M+H]⁺ is 325.9815, found 325.9822

methyl 3-(2-((fluorosulfonyl)methyl)-5-oxopyrrolidin-1-yl)thiophene-2-carboxylate (2p)

Compound **2p** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 3:1 to 1:1) to give a foamed solid (19.3 mg, 60% yield).

¹H NMR (400 MHz, DMSO- d_6) δ 7.94 (d, J = 5.3 Hz, 1H), 7.19 (d, J = 5.3 Hz, 1H), 4.67 (ddd, J = 11.2, 7.2, 3.4 Hz, 1H), 4.36 (ddd, J = 14.7, 8.8, 5.8 Hz, 1H), 4.03 (ddd, J = 14.9, 5.4, 3.3 Hz, 1H), 3.78 (s, 3H), 2.70 – 2.56 (m, 1H), 2.53 – 2.31 (m, 2H), 2.17 (ddd, J = 15.6, 8.3, 3.6 Hz, 1H). ¹³C NMR (126 MHz, DMSO- d_6) δ 173.6, 160.7, 139.1, 131.6, 128.4, 125.6, 55.6, 52.5 (d, J = 11.9 Hz), 52.1, 28.9, 24.1. ¹⁹F NMR (376 MHz, DMSO- d_6) δ 59.85. **HRMS (ESI)**: m/z calculated for [M] (C₁₁H₁₂NO₅FS₂) from [M+H]⁺ is 344.0033, found 344.0023

$(1-(6-methoxypyridin-3-yl)-5-oxopyrrolidin-2-yl) methane sulfonyl\ fluoride\ (2q)$

Compound **2q** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 3:1 to 1:1) to give a white solid (11.5 mg, 40% yield).

¹H NMR (400 MHz, DMSO- d_6) δ 8.18 (d, J = 2.6 Hz, 1H), 7.77 (dd, J = 8.8, 2.7 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 4.79 (td, J = 7.9, 3.8 Hz, 1H), 4.41 – 4.24 (m, 1H), 4.13 (ddd, J = 15.0, 5.1, 3.1 Hz, 1H), 3.86 (s, 3H), 2.73 – 2.58 (m, 1H), 2.43 (ddd, J = 13.6, 11.1, 6.6 Hz, 2H), 2.25 – 2.02 (m, 1H). ¹³C NMR (101 MHz, DMSO- d_6) δ 173.8, 161.5, 143.3, 136.2, 127.3, 110.5, 54.7, 53.3, 52.1 (d, J = 11.7 Hz), 29.4, 23.2. ¹⁹F NMR (376 MHz, DMSO- d_6) δ 60.66. **HRMS (ESI):** m/z calculated for [M] (C₁₁H₁₃N₂O₄FS) from [M+H]⁺ is 289.0653, found 289.0644

(1-(4-chlorophenyl)-4-methyl-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2r)

Compound **2r** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (21.4 mg, 70% yield, dr = 2.5:1).

 1 H NMR (500 MHz, CDCl₃) δ 7.42 (dd, J = 21.0, 8.9 Hz, 4H), 4.73 (dd, J = 9.8, 8.1 Hz, 1H), 3.60 (dd, J = 12.0, 2.7 Hz, 1H), 3.54 – 3.32 (m, 1H), 2.89 – 2.70 (m, 1H), 2.57 (dd, J = 12.8, 9.2 Hz, 1H), 2.27 – 2.09 (m, 1H), 1.32 (d, J = 7.0 Hz, 3H). 13 C NMR (101 MHz, CDCl₃) δ 175.7, 134.8, 131.9, 129.9, 123.8, 52.8, 52.1 (d, J = 14.6 Hz), 35.6, 31.9, 15.9. 19 F NMR (376 MHz, CDCl₃) δ 60.21. **HRMS** (ESI): m/z calculated for [M] (C₁₂H₁₃NO₃FSCl) from [M+H]* is 306.0361, found 306.0356

(1-(4-chlorophenyl)-4,4-dimethyl-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2s)

Compound **2s** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (23.7 mg, 74% yield).

 1 H NMR (400 MHz, ĆDCl₃) δ 7.49 – 7.31 (m, 2H), 7.29 (dd, J = 8.5, 1.5 Hz, 2H), 4.64 (dt, J = 12.1, 7.4 Hz, 1H), 3.90 – 3.67 (m, 1H), 3.41 – 3.12 (m, 1H), 2.56 (dd, J = 13.3, 7.2 Hz, 1H), 2.02 (dd, J = 13.3, 7.1 Hz, 1H), 1.34 (s, 3H), 1.25 (s, 3H). 13 C NMR (101 MHz, CDCl₃) δ 178.5, 134.6, 132.6, 129.9, 125.2, 54.2 (d, J = 15.3 Hz), 51.2, 40.9, 40.2, 25.8, 25.2. 19 F NMR (376 MHz, CDCl₃) δ 60.73. **HRMS (ESI):** m/z calculated for [M] (C₁₃H₁₅NO₃FSCl) from [M+H]⁺ is 320.0518, found 320.0509

(1-(4-chlorophenyl)-5-oxo-4-(p-tolyl)pyrrolidin-2-yl)methanesulfonyl fluoride (2t)

Compound **2t** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (27.5 mg, 72% yield, dr = 2.8:1).

¹H NMR (400 MHz, $\dot{\text{CDCl}_3}$) δ 7.48 (d, \dot{J} = 9.0 Hz, 2H), 7.42 (d, \dot{J} = 9.0 Hz, 2H), 7.16 (q, \dot{J} = 8.2 Hz, 4H), 4.84 (td, \dot{J} = 7.5, 2.6 Hz, 1H), 3.95 (t, \dot{J} = 9.2 Hz, 1H), 3.71 – 3.61 (m, 1H), 3.59 – 3.48 (m, 1H), 2.83 – 2.57 (m, 2H), 2.34 (s, 3H). ¹³C NMR (101 MHz, $\dot{\text{CDCl}_3}$) δ 173.6, 137.6, 134.7, 134.4, 132.2, 129.9, 129.8, 127.9, 124.0, 52.9, 52.2 (d, \dot{J} = 15.0 Hz), 46.7, 32.8, 21.1. ¹⁹F NMR (376 MHz, $\dot{\text{CDCl}_3}$) δ 60.39. **HRMS (ESI):** m/z calculated for [M] ($\dot{\text{C}}_{18}H_{17}NO_3FSCI$) from [M+H]+ is 382.0674, found 382.0659

(4-benzyl-1-(4-chlorophenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2u)

Compound 2u was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (24.4 mg, 64% yield, dr = 2:1).

¹H NMR (400 MHz, CDCl₃) (dr = 1:2) δ 7.49 – 7.12 (m, 27H), 4.64 – 4.42 (m, 1H), 4.42 – 4.20 (m, 2H), 3.54 (ddd, J = 14.6, 3.8, 2.3 Hz, 2H), 3.42 – 3.01 (m, 10H), 2.94 (dd, J = 13.6, 7.8 Hz, 2H), 2.84 – 2.67 (m, 1H), 2.41 – 2.31 (m, 4H), 2.18 – 2.06 (m, 1H), 2.07 – 1.89 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 174.5, 137.8, 134.5, 132.2, 129.9, 129.2, 128.9, 127.1, 124.2, 53.0, 52.6 (d, J = 14.8 Hz),

42.5, 36.7, 29.4. 19 F NMR (376 MHz, CDCl₃) δ 60.28, 59.94. **HRMS (ESI):** m/z calculated for [M] (C₁₈H₁₇NO₃FSCl) from [M+Na]⁺ is 404.0494, found 404.0476

(1-(4-chlorophenyl)-4-(1,3-dioxoisoindolin-2-yl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2v)

Compound 2v was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (33.2 mg, 76% yield, dr = 2:1).

¹H NMR (400 MHz, CDCl₃) δ 7.86 (dd, J = 5.4, 3.0 Hz, 2H), 7.80 – 7.70 (m, 2H), 7.53 – 7.32 (m, 4H), 5.26 (ddd, J = 10.8, 7.1, 3.0 Hz, 1H), 5.04 – 4.93 (m, 1H), 3.81 – 3.45 (m, 2H), 2.94 (dt, J = 14.3, 8.4 Hz, 1H), 2.86 – 2.66 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 168.9, 167.4, 134.6, 134.4, 133.2, 131.7, 130.1, 124.9, 123.8, 53.0, 52.7 (d, J = 15.2 Hz), 48.7, 28.8. ¹⁹F NMR (376 MHz, CDCl₃) δ 60.67. **HRMS (ESI):** m/z calculated for [M] ($C_{19}H_{14}N_2O_5FSCI$) from [M+Na]⁺ is 459.0188, found 459.0183

tert-butyl (1-(4-chlorophenyl)-5-((fluorosulfonyl)methyl)-2-oxopyrrolidin-3-yl)carbamate (2w)

Compound **2w** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (20.3 mg, 50% yield, dr = 1.5:1).
¹H NMR (400 MHz, CDCl₃) δ 7.58 – 7.34 (m, 4H), 5.18 (d, J = 5.9 Hz, 1H), 4.79 (dd, J = 11.8, 7.4 Hz, 1H), 4.45 (d, J = 5.8 Hz, 1H), 3.69 – 3.36 (m, 2H), 2.89 (dd, J = 13.6, 8.8 Hz, 1H), 2.61 – 2.26 (m, 1H), 1.45 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 171.4, 155.7, 134.3, 132.6, 130.1, 123.9, 80.8, 52.2, 52.0 (d, J = 15.1 Hz), 51.3, 31.6, 28.4. ¹⁹F NMR (376 MHz, CDCl₃) δ 60.19. **HRMS (ESI):** m/z calculated for [M] ($C_{16}H_{20}N_2O_5FSCI$) from [M+Na]* is 429.0658, found 429.0641

(9H-fluoren-9-yl)methyl (1-(4-chlorophenyl)-5-((fluorosulfonyl)methyl)-2-oxopyrrolidin-3-yl)carbamate (2x)

Compound 2x was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (23.8 mg, 45% yield, dr = 2:1).

¹H NMR (500 MHz, DMSO- d_6 , dr = 2:1) δ 7.90 (d, J = 7.5 Hz, 7H), 7.81 (d, J = 8.6 Hz, 2H), 7.72 (t, J = 8.2 Hz, 6H), 7.57 (d, J = 8.8 Hz, 4H), 7.51 (t, J = 10.0 Hz, 6H), 7.42 (t, J = 7.1 Hz, 6H), 7.35 (dt, J = 12.2, 7.9 Hz, 8H), 4.98 (t, J = 7.1 Hz, 2H), 4.76 (d, J = 5.2 Hz, 1H), 4.68 (d, J = 10.3 Hz, 2H), 4.59 – 4.47 (m, 2H), 4.37 (ddd, J = 14.3, 9.6, 5.8 Hz, 7H), 4.25 (t, J = 6.5 Hz, 4H), 4.12 (d, J = 14.8 Hz, 4H), 2.76 (dt, J = 12.4, 9.0 Hz, 1H), 2.40 (dd, J = 20.6, 11.5 Hz, 2H), 2.22 – 1.91 (m, 2H). ¹³C NMR (126 MHz, DMSO- d_6) δ 171.5, 155.9, 143.8, 140.7, 135.6, 135.1, 130.8, 129.9, 129.0, 129.0, 127.6, 127.0, 126.6, 125.1, 124.6, 120.1, 65.6, 52.9 (d, J = 12.0 Hz), 51.3, 51.2, 51.0, 50.6, 50.5, 46.6, 30.9, 29.5. ¹⁹F NMR (376 MHz, DMSO- d_6) δ 61.33, 59.85. **HRMS (ESI):** m/z calculated for [M] ($C_{26}H_{22}N_2O_5FSCI$) from [M+Na]* is 551.0814, found 551.0805

2-(benzyloxy)-1-(1-(4-chlorophenyl)-5-oxopyrrolidin-2-yl)ethanesulfonyl fluoride (2y)

Compound **2y** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (23.0 mg, 56% yield, dr = 1:1).

 1 H NMR (400 MHz, CDCl₃) δ 7.42 – 7.33 (m, 5H), 7.31 – 7.20 (m, 4H), 5.01 (t, J = 5.1 Hz, 1H), 4.50 (s, 2H), 3.93 – 3.75 (m, 3H), 2.69 – 2.51 (m, 2H), 2.50 – 2.38 (m, 2H). 13 C NMR (101 MHz, CDCl₃) δ 173.9, 136.1, 134.3, 132.5, 129.9, 128.8, 128.5, 128.1, 125.1, 74.3, 63.2, 62.2 (d, J = 10.1 Hz), 57.0, 30.7, 19.6. 19 F NMR (376 MHz, CDCl₃) δ 58.65. **HRMS (ESI)**: m/z calculated for [M] ($C_{19}H_{19}NO_4FSCI$) from [M+H]⁺ is 412.0780, found 412.0769

1-(1-(4-chlorophenyl)-5-oxopyrrolidin-2-yl)-3-phenylpropane-1-sulfonyl fluoride (2z)

Compound **2z** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (23.0 mg, 58% yield, *dr* = 1.6:1).

¹H NMR (400 MHz, $\dot{C}DCl_3$) δ 7.38 – 7.21 (m, 5H), 7.17 – 6.97 (m, 4H), 4.52 (ddd, J = 12.9, 7.8, 3.1 Hz, 1H), 3.54 (td, J = 6.3, 3.0 Hz, 1H), 2.88 – 2.73 (m, 3H), 2.63 – 2.46 (m, 2H), 2.46 – 2.34 (m, 2H), 2.14 – 1.93 (m, 1H). ¹³C NMR (101 MHz, $\dot{C}DCl_3$) δ 173.7, 138.2, 134.5, 132.2, 129.6, 129.2, 128.4, 127.3, 125.5, 60.4 (d, J = 8.9 Hz), 59.4, 32.5, 30.2, 28.4, 18.5. ¹⁹F NMR (376 MHz, $\dot{C}DCl_3$) δ 60.05. **HRMS (ESI):** m/z calculated for [M] ($\dot{C}_{19}H_{19}NO_3FSCl$) from [M+H]⁺ is 396.0831, found 396.0817

6-(4-chlorophenyl)-7-oxo-6-azabicyclo[3.2.1]octane-4-sulfonyl fluoride (2aa)

Compound **2aa** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (22.2 mg, 70% yield, *dr* = 1:1).

 1 H NMR (400 MHz, CDCl₃) δ 7.59 (d, J = 8.8 Hz, 2H), 7 .38 (d, J = 8.8 Hz, 2H), 4.82 (d, J = 2.0 Hz, 1H), 3.85 (d, J = 2.2 Hz, 1H), 2.78 (s, 1H), 2.48 – 2.28 (m, 3H), 2.17 – 1.92 (m, 3H). 13 C NMR (101 MHz, CDCl₃) δ 175.4, 135.3, 131.0, 129.8, 121.4, 56.6, 56.2 (d, J = 11.0 Hz), 40.7, 30.4, 21.8, 19.5. 19 F NMR (376 MHz, CDCl₃) δ 54.83. **HRMS (ESI)**: m/z calculated for [M] (C₁₃H₁₃NO₃FSCl) from [M+H]* is 318.0361, found 318.0369

1-(4-chlorophenyl)-2-oxooctahydrocyclopenta[b]pyrrole-6-sulfonyl fluoride (2ab)

Compound **2ab** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 10:1) to give a white solid (17.5 mg, 55% yield, dr > 20:1).

¹H NMR (400 MHz, $\dot{C}DCl_3$) δ 7.41 (s, 4H), 5.12 (d, J = 7.4 Hz, 1H), 3.73 (dd, J = 4.9, 2.7 Hz, 1H), 3.17 (d, J = 3.5 Hz, 1H), 2.92 (dd, J = 17.9, 9.8 Hz, 1H), 2.53 – 2.23 (m, 4H), 1.92 – 1.65 (m, 1H). ¹³C NMR (101 MHz, $\dot{C}DCl_3$) δ 172.8, 134.5, 132.4, 129.7, 125.0, 66.2, 65.5 (d, J = 12.7 Hz), 37.8, 35.2, 32.2, 27.1. ¹⁹F NMR (376 MHz, $\dot{C}DCl_3$) δ 50.00. **HRMS (ESI)**: m/z calculated for [M] ($\dot{C}_{13}H_{13}NO_3FSCl$) from [M+H]⁺ is 318.0361, found 318.0346

1-(4-chlorophenyl)-2-oxooctahydro-3,5-methanocyclopenta[b]pyrrole-6-sulfonyl fluoride (2ac)

Compound **2ac** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (18.5 mg, 56% yield, dr > 20:1).

¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, J = 8.9 Hz, 2H), 7.35 (d, J = 8.9 Hz, 2H), 4.72 (d, J = 4.5 Hz, 1H), 3.46 (s, 1H), 3.32 (s, 1H), 3.14 (s, 1H), 2.73 (dd, J = 11.0, 4.4 Hz, 1H), 2.36 (d, J = 11.9 Hz, 1H), 2.30 – 2.14 (m, 1H), 1.79 (dd, J = 28.8, 12.8 Hz, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 176.8, 136.3, 130.6, 129.4, 121.2, 69.0 (d, J = 11.6 Hz), 63.5, 44.3, 42.6, 40.8, 34.8, 34.6. ¹⁹F NMR (376 MHz, CDCl₃) δ 54.98. **HRMS (ESI):** m/z calculated for [M] (C₁₄H₁₃NO₃FSCl) from [M+H]⁺ is 330.0361, found 330.0351

2-(4-chlorophenyl)-3-oxo-2-azabicyclo[2.2.1]heptane-6-sulfonyl fluoride (2ad)

Compound **2ad** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (8.5 mg, 28% yield, *dr* = 6:1).

¹H NMR (400 MHz, $CDCl_3$) δ 7.46 – 7.40 (m, 2H), 7.39 – 7.32 (m, 2H), 4.85 (s, 1H), 3.85 (dd, J = 7.5, 6.2 Hz, 1H), 3.16 (s, 1H), 2.56 – 2.48 (m, 1H), 2.47 – 2.36 (m, 1H), 2.20 (dt, J = 10.8, 6.1 Hz, 2H). ¹³C NMR (101 MHz, $CDCl_3$) δ 174.2, 135.1, 130.5, 129.7, 119.9, 62.0, 60.7 (d, J = 13.7 Hz), 46.0, 36.9, 28.9. ¹⁹F NMR (376 MHz, $CDCl_3$) δ 53.41. **HRMS (ESI):** m/z calculated for [M] ($C_{12}H_{11}NO_3FSCI$) from [M+H]* is 304.0205, found 304.0218

(3-(4-chlorophenyl)-2-oxooxazolidin-4-yl)methanesulfonyl fluoride (2ae)

Compound **2ae** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 10:1) to give a white solid (14.1 mg, 48% yield).

¹H NMR (400 MHz, $CDCl_3$) δ 7.51 – 7.35 (m, 4H), 4.95 (dddd, J = 10.1, 7.9, 4.0, 2.2 Hz, 1H), 4.74 (dd, J = 9.5, 8.2 Hz, 1H), 4.54 (dd, J = 9.7, 4.0 Hz, 1H), 3.75 (dt, J = 14.8, 2.5 Hz, 1H), 3.62 (ddd, J = 14.9, 10.0, 4.9 Hz, 1H). ¹³C NMR (101 MHz, $CDCl_3$) δ 154.1, 133.5, 132.2, 130.2, 122.7, 66.0, 52.1, 51.5 (d, J = 16.2 Hz). ¹⁹F NMR (376 MHz, $CDCl_3$) δ 59.98. **HRMS (ESI):** m/z calculated for [M] ($C_{10}H_9NO_4FSCI$) from [M+H]* is 293.9998, found 293.9989

(3-(4-chlorophenyl)-4-methyl-2-oxooxazolidin-4-yl)methanesulfonyl fluoride (2af)

Compound **2af** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (19.1 mg, 62% yield).

¹H NMR (400 MHz, CDCl₃) δ 7.54 – 7.36 (m, 2H), 7.22 – 7.10 (m, 2H), 4.81 (d, J = 9.7 Hz, 1H), 4.31 (d, J = 9.7 Hz, 1H), 3.81 (dd, J = 14.6, 5.7 Hz, 1H), 3.51 (d, J = 14.6 Hz, 1H), 1.65 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 155.8, 135.7, 131.7, 130.8, 130.4, 72.0, 60.6, 56.6 (d, J = 14.5 Hz), 24.1 (d, J = 2.1 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ 65.40. **HRMS (ESI)**: m/z calculated for [M] (C₁₁H₁₁NO₄FSCl) from [M+Na]⁺ is 329.9974, found 329.9958

(3-(4-chlorophenyl)-5-ethyl-2-oxooxazolidin-4-yl)methanesulfonyl fluoride (2ag)

Compound **2ag** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (22.5 mg, 70% yield, *dr* = 1.6:1).

 1 H NMR (400 MHz, CDCl₃) δ 7.48 – 7.39 (m, 4H), 4.64 – 4.58 (m, 1H), 4.54 (dt, J = 9.4, 2.6 Hz, 1H), 3.76 – 3.58 (m, 2H), 1.95 – 1.85 (m, 2H), 1.11 (t, J = 7.4 Hz, 3H). 13 C NMR (101 MHz, CDCl₃) δ 153.5, 133.7, 131.8, 130.1, 122.3, 79.1, 56.4, 51.5 (d, J = 15.5 Hz), 28.1, 8.7. 19 F NMR (376 MHz, CDCl₃) δ 60.46. **HRMS (ESI):** m/z calculated for [M] ($C_{12}H_{13}NO_4$ FSCI) from [M+Na]* is 344.0130, found 344.0115

1-(3-(4-chlorophenyl)-2-oxooxazolidin-4-yl)ethanesulfonyl fluoride (2ah)

50.46. HRMS (ESI): m/z calculated for [M] (C₁₁H₁₁NO₄FSCI) from [M+Na]+ is 329.9974, found 329.9964

Compound **2ah** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (22.1 mg, 72% yield, dr = 1:1).

¹H NMR (400 MHz, CDCl₃) δ 7.43 (s, 4H), 5.30 – 5.02 (m, 1H), 4.75 – 4.43 (m, 2H), 3.98 – 3.53 (m, 1H), 1.54 (d, J = 7.1 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 154.5, 133.3, 132.2, 130.2, 122.9, 61.8, 56.0 (d, J = 12.4 Hz), 54.6, 7.7.

¹⁹F NMR (376 MHz, CDCl₃) δ

1-(3-(4-chlorophenyl)-2-oxooxazolidin-4-yl)butane-1-sulfonyl fluoride (2ai)

Compound **2ai** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ ethyl acetate 5:1) to give a white solid (21.5 mg, 64% yield, *dr* = 1.5:1).

¹H NMR (400 MHz, $\dot{\text{CDCl}_3}$) δ 7.52 $\dot{\text{-}}$ 7.27 (m, 4H), 4.93 (dt, J = 8.2, 5.0 Hz, 1H), 4.71 $\dot{\text{-}}$ 4.53 (m, 2H), 3.60 (td, J = 6.6, 2.8 Hz, 1H), 2.04 (td, J = 14.8, 7.0 Hz, 1H), 1.85 $\dot{\text{-}}$ 1.61 (m, 1H), 1.61 $\dot{\text{-}}$ 1.48 (m, 2H), 0.97 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 154.8, 133.9, 132.3, 129.9, 124.2, 63.0, 61.4 (d, J = 10.4 Hz), 56.1, 28.6, 20.2, 13.6. ¹⁹F NMR (376 MHz, CDCl₃) δ 59.03. **HRMS (ESI):** m/z calculated for [M] (C₁₃H₁₅NO₄FSCl) from [M+Na]* is 358.0287, found 358.0271

3-(4-chlorophenyl)-2-oxooctahydrobenzo[d]oxazole-4-sulfonyl fluoride (2aj)

Compound **2aj** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1) to give a white solid (18.7 mg, 56% yield, dr = 6:1).

Th NMR (400 MHz, CDCl₃) δ 7.45 – 7.38 (m, 2H), 7.38 – 7.31 (m, 2H), δ 4.95 (dd, J = 11.1, 5.4 Hz, 1H), 4.90 (dd, J = 6.4, 3.1 Hz, 1H), 3.77 (d, J = 3.5 Hz, 1H), 2.21 – 1.99 (m, 4H), 1.91 – 1.70 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 154.9, 134.0, 132.3, 129.8, 124.1, 72.4, 59.5 (d, J = 12.3 Hz), 54.2, 25.6, 21.3, 16.0. ¹⁹F NMR (376 MHz, CDCl₃) δ 53.08. **HRMS (ESI)**: m/z calculated for [M] ($C_{13}H_{13}NO_4FSCI$) from [M+Na]* is 356.0130, found 356.0117

(3-(4-chlorophenyl)-2-oxo-1-phenylimidazolidin-4-yl)methanesulfonyl fluoride (2ak)

Compound **2ak** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1 to 2:1) to give a white solid (7.7 mg, 21% yield).

¹H NMR (400 MHz, DMSO- d_6) δ 7.66 – 7.52 (m, 4H), 7.53 – 7.44 (m, 2H), 7.39 (dd, J = 10.8, 5.3 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H), 5.21 (d, J = 8.2 Hz, 1H), 4.60 – 4.43 (m, 1H), 4.37 – 4.20 (m, 2H), 4.03 (dd, J = 9.7, 3.6 Hz, 1H). ¹³C NMR (101 MHz, DMSO- d_6) δ 153.6, 139.4, 136.2, 128.8, 128.8, 128.5, 123.4, 123.0, 118.1, 51.2 (d, J = 11.8 Hz), 47.9, 46.2. ¹⁹F NMR (376 MHz, DMSO- d_6) δ 61.37. **HRMS (ESI):** m/z calculated for [M] ($C_{16}H_{14}N_2O_3FSCI$) from [M+Na]* is 391.0290, found 391.0300

(1-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenyl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2al)

Compound **2al** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 2:1 to 1:1) to give a faint yellow solid (15.5 mg, 35% yield).

¹H NMR (500 MHz, DMSO- d_6) δ 11.77 (s, 1H), 8.01 (d, J = 8.6 Hz, 2H), 7.70 (d, J = 8.6 Hz, 2H), 6.76 (s, 1H), 5.02 (t, J = 7.6 Hz, 1H), 4.44 – 4.28 (m, 1H), 4.13 (d, J = 14.9 Hz, 1H), 2.84 – 2.63 (m, 1H), 2.43 (dd, J = 21.7, 10.3 Hz, 2H), 2.25 (s, 6H), 2.16 (t, J = 10.4 Hz, 1H). ¹³C NMR (126 MHz, DMSO- d_6) δ 173.8, 156.0, 140.2, 131.1, 128.9, 128.3, 126.3, 121.6, 53.8, 51.6 (d, J = 11.8 Hz), 30.0, 22.8, 22.7. ¹⁹F NMR (376 MHz, DMSO- d_6) δ 60.54. **HRMS (ESI):** m/z calculated for [M] (C₁₇H₁₉N₄O₅FS₂) from [M+H]⁺ is 443.0854, found 443.0870

(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (2am)

Compound **2am** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 1:1) to give a white solid (20.3 mg, 48% yield).

¹H NMR (400 MHz, DMSO- d_6 , dr = 1:1) δ 11.01 (s, 1H), 7.72 (dd, J = 7.1, 1.6 Hz, 1H), 7.70 – 7.58 (m, 2H), 5.22 – 5.06 (m, 1H), 4.91 – 4.77 (m, 1H), 4.46 – 4.20 (m, 3H), 4.16 – 3.99 (m, 1H), 2.99 – 2.77 (m, 1H), 2.74 – 2.42 (m, 5H), 2.41 – 2.27 (m, 1H), 2.25 – 2.12

(m, 1H), 1.99 (ddd, J = 14.5, 7.3, 1.9 Hz, 1H). ¹³C NMR (101 MHz, DMSO- d_6) δ 173.0, 172.8, 170.8, 167.4, 139.1, 133.1, 129.2, 128.7, 126.1, 122.2, 54.9, 52.5 (d, J = 11.8 Hz), 51.3, 46.5, 31.1, 29.3, 23.9, 22.6. ¹⁹F NMR (376 MHz, DMSO- d_6) δ 60.99, 60.31. **HRMS (ESI):** m/z calculated for [M] (C₁₈H₁₈N₃O₆FS) from [M+H]* is 424.0973, found 424.0966

2-isopropyl-5-methylcyclohexyl 4-(2-((fluorosulfonyl)methyl)-5-oxopyrrolidin-1-yl)benzoate (2an)

Compound **2an** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ethyl acetate 5:1 to 3:1) to give a white solid (25.5 mg, 58% yield, dr = 1:1).

¹H NMR (400 MHz, CDCl₃, dr = 1:1) δ 8.11 (d, J = 8.4 Hz, 2H), 7.61 – 7.46 (m, 2H), 5.07 – 4.77 (m, 2H), 3.69 (ddd, J = 14.6, 5.8, 3.9 Hz, 1H), 3.44 (ddd, J = 14.6, 9.9, 2.6 Hz, 1H), 2.86 – 2.55 (m, 3H), 2.40 – 2.23 (m, 1H), 2.15 – 2.05 (m, 1H), 1.93 (tdd, J = 13.7, 6.9, 2.7 Hz, 1H), 1.73 (d, J = 11.5 Hz, 2H), 1.60 – 1.50 (m, 2H), 1.17 – 1.04 (m, 2H), 0.98 – 0.86 (m, 7H), 0.79 (d, J = 6.9 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 173.4, 165.2, 139.8, 131.2, 128.7, 122.1, 75.2, 54.3, 52.8 (d, J = 13.9 Hz), 47.3, 41.0, 34.4, 31.5, 30.4, 26.6, 23.7, 22.1, 20.8, 16.6. ¹⁹F NMR (376 MHz, CDCl₃) δ 60.63, 60.54. **HRMS (ESI)**: m/z calculated for [M] ($C_{22}H_{30}NO_5FS$) from [M+Na]+ is 462.1721, found 462.1716

13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl 4-(2-((fluorosulfonyl)methyl)-5-oxopyrrolidin-1-yl)benzoate (2ao)

Compound **2ao** was prepared according to **General Procedure**. The residue was purified by flash column chromatography on silica (petroleum ether/ ethyl acetate 3:1 to 1:1) to give a white solid (25.5 mg, 46% yield).

¹H NMR (400 MHz, $\dot{\text{CDCl}_3}$) δ 8.27 (d, J = 8.9 Hz, 2H), 7.64 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 8.5 Hz, 1H), 7.05 – 6.79 (m, 2H), 5.01 – 4.82 (m, 1H), 3.72 (ddd, J = 14.6, 3.9, 1.9 Hz, 1H), 3.48 (ddd, J = 14.6, 9.8, 2.5 Hz, 1H), 3.01 – 2.90 (m, 2H), 2.84 – 2.61 (m, 3H), 2.56 – 2.39 (m, 2H), 2.32 (ddd, J = 11.6, 8.9, 3.7 Hz, 2H), 2.23 – 1.87 (m, 5H), 1.68 – 1.58 (m, 1H), 1.57 – 1.40 (m, 4H), 0.92 (s, 3H). ¹³C NMR (126 MHz, $\dot{\text{CDCl}_3}$) δ 220.9, 173.4, 164.6, 148.8, 140.7, 138.3, 137.7, 131.8, 127.2, 126.6, 121.8, 121.7, 118.9, 54.2, 52.8 (d, J = 15.0 Hz), 50.5, 48.0, 44.3, 38.1, 35.9, 31.6, 30.4, 29.5, 26.4, 25.9, 23.6, 21.7, 13.9. ¹⁹F NMR (376 MHz, $\dot{\text{CDCl}_3}$) δ 60.60. **HRMS** (ESI): m/z calculated for [M] ($\dot{\text{C}_{30}}H_{32}NO_6FS$) from [M+H]* is 554.2007, found 554.2014

methyl (5-oxo-1-phenylpyrrolidin-2-yl)methanesulfonate (D1)

 1 H NMR (400 MHz, CDCl₃) δ 7.53 – 7.31 (m, 4H), 7.32 – 7.19 (m, 1H), 4.89 – 4.57 (m, 1H), 3.85 (s, 3H), 3.40 (dd, J = 14.3, 2.0 Hz, 1H), 3.11 (dd, J = 14.2, 10.2 Hz, 1H), 2.76 – 2.50 (m, 3H), 2.35 – 2.13 (m, 1H). 13 C NMR (101 MHz, CDCl₃) δ 173.7, 136.3, 129.6, 126.6, 123.5, 55.6, 55.1, 51.8, 30.6, 24.1. **HRMS (ESI)**: m/z calculated for [M] (C₁₂H₁₅NO₄S) from [M+H]* is 270.0795, found 270.0769

phenyl (5-oxo-1-phenylpyrrolidin-2-yl)methanesulfonate (D2)

 1 H NMR (400 MHz, CDCl₃) δ 7.47 – 7.23 (m, 8H), 7.14 (d, J = 8.0 Hz, 2H), 4.97 – 4.58 (m, 1H), 3.59 (dd, J = 14.2, 2.1 Hz, 1H), 3.28 (dd, J = 14.2, 10.3 Hz, 1H), 2.84 – 2.53 (m, 3H), 2.50 – 2.20 (m, 1H). 13 C NMR (101 MHz, CDCl₃) δ 173.7, 148.7, 136.3, 130.2, 129.7, 127.6, 126.8, 123.9, 121.9, 55.4, 52.6, 30.5, 24.1. **HRMS (ESI)**: m/z calculated for [M] ($C_{17}H_{17}NO_4S$) from [M+H]* is 332.0951, found 332.0949

ethyl 1,2-dimethyl-5-((((5-oxo-1-phenylpyrrolidin-2-yl)methyl)sulfonyl)oxy)-1H-indole-3-carboxylate (D3)

 1 H NMR (400 MHz, CDCl₃) δ 7.94 (d, J = 2.4 Hz, 1H), 7.47 – 7.32 (m, 4H), 7.25 – 7.17 (m, 2H), 7.02 (dd, J = 8.8, 2.4 Hz, 1H), 4.96 – 4.71 (m, 1H), 4.36 (q, J = 7.1 Hz, 2H), 3.64 (s, 3H), 3.64 – 3.58 (m, 1H), 3.29 (dd, J = 14.1, 10.3 Hz, 1H), 2.73 (s, 3H), 2.70 – 2.54 (m, 3H), 2.46 – 2.30 (m, 1H), 1.40 (t, J = 7.1 Hz, 3H). 13 C NMR (101 MHz, CDCl₃) δ 173.7, 165.4, 147.0, 143.9, 136.3, 135.0, 129.5, 127.2, 126.5, 123.6, 115.9, 114.3, 110.0, 104.5, 59.7, 55.3, 52.3, 30.5, 29.9, 24.0, 14.6, 12.0. **HRMS (ESI):** m/z calculated for [M] ($C_{24}H_{26}N_2O_6S$) from [M+Na]* is 493.1404, found 493.1403

((5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)methyl phenylpyrrolidin-2-yl)methanesulfonate (D4)

(5-oxo-1-

 $^{1}\text{H NMR } (400 \text{ MHz, CDCl}_{3}) \, \delta \, 7.48 - 7.34 \, (\text{m, 4H}), \, 7.28 - 7.15 \, (\text{m, 1H}), \, 5.43 \, (\text{dd, } \textit{J} = 51.0, \, 5.0 \, \text{Hz, 1H}), \, 4.82 - 4.68 \, (\text{m, 1H}), \, 4.60 \, (\text{ddd, } \textit{J} = 7.8, \, 3.7, \, 2.7 \, \text{Hz, 1H}), \, 4.43 - 4.26 \, (\text{m, 3H}), \, 4.18 \, (\text{ddd, } \textit{J} = 7.8, \, 3.2, \, 2.0 \, \text{Hz, 1H}), \, 4.06 \, (\text{ddd, } \textit{J} = 8.4, \, 4.5, \, 1.7 \, \text{Hz, 1H}), \, 3.50 \, (\text{ddd, } \textit{J} = 36.2, \, 14.3, \, 2.3 \, \text{Hz, 1H}), \, 3.22 \, (\text{ddd, } \textit{J} = 34.0, \, 14.3, \, 10.4 \, \text{Hz, 1H}), \, 2.76 - 2.62 \, (\text{m, 1H}), \, 2.63 - 2.47 \, (\text{m, 2H}), \, 2.40 - 2.25 \, (\text{m, 1H}), \, 1.55 - 1.37 \, (\text{m, 6H}), \, 1.35 - 1.24 \, (\text{m, 6H}). \, ^{13}\text{C NMR } \, (126 \, \text{MHz, CDCl}_{3}) \, \delta \, 173.9, \, 136.4, \, 129.5, \, 126.4, \, 123.6, \, 110.0, \, 109.1, \, 96.2, \, 70.7, \, 70.2, \, 69.7, \, 66.3, \, 55.3, \, 52.9, \, 30.7, \, 25.9, \, 24.9, \, 24.4, \, 23.9. \, \text{HRMS } \, \text{(ESI): } \textit{m/z} \, \text{calculated for [M]} \, \, (\text{C}_{23}\text{H}_{31}\text{NO}_{9}\text{S}) \, \text{from [M+H]}^+ \, \text{is } 520.1612, \, \text{found } 520.1598$

$$\begin{array}{c}
O \\
O = S - NH_2 \\
N \\
O
\end{array}$$

(5-oxo-1-phenylpyrrolidin-2-yl)methanesulfonamide (D5)

 1 H NMR (400 MHz, DMSO- $^{\prime}$ $^{\prime}$ 6) δ 7.51 (dd, $^{\prime}$ J = 8.5, 0.9 Hz, 2H), 7.42 (t, $^{\prime}$ J = 7.9 Hz, 2H), 7.22 (t, $^{\prime}$ J = 7.3 Hz, 1H), 7.09 (s, 2H), 4.83 – 4.47 (m, 1H), 3.31 (dd, $^{\prime}$ J = 13.9, 10.4 Hz, 1H), 3.07 (dd, $^{\prime}$ J = 13.9, 1.5 Hz, 1H), 2.76 – 2.59 (m, 1H), 2.47 – 2.32 (m, 2H), 2.28 – 2.12 (m, 1H). 13 C NMR (101 MHz, DMSO- $^{\prime}$ $^{\prime}$ 6) δ 173.5, 137.2, 129.0, 125.3, 122.9, 56.0, 54.9, 30.2, 23.6. **HRMS (ESI)**: $^{\prime\prime}$ 7 calculated for [M] ($^{\prime}$ 61 ($^{\prime}$ 1 H₁4N₂O₃S) from [M+Na] $^{+}$ is 277.0617, found 277.0601

5-((morpholinosulfonyl)methyl)-1-phenylpyrrolidin-2-one (D6)

 1 H NMR (400 MHz, CDCl₃) δ 7.52 – 7.35 (m, 4H), 7.29 – 7.16 (m, 1H), 4.88 – 4.55 (m, 1H), 3.82 – 3.44 (m, 4H), 3.23 – 3.05 (m, 5H), 2.85 (dd, J = 13.4, 10.3 Hz, 1H), 2.74 – 2.51 (m, 3H), 2.38 – 2.24 (m, 1H). 13 C NMR (101 MHz, CDCl₃) δ 173.8, 136.6, 129.5, 126.3, 123.1, 66.4, 54.9, 50.1, 45.6, 30.7, 24.4. **HRMS (ESI):** m/z calculated for [M] ($C_{15}H_{20}N_2O_4S$) from [M+H]⁺ is 325.1217, found 325.1216

(5-oxo-1-phenylpyrrolidin-2-yl)methanesulfonyl azide (D7)

 1 H NMR (400 MHz, CDCl₃) δ 7.50 - 7.35 (m, 4H), 7.33 - 7.22 (m, 1H), 4.88 - 4.62 (m, 1H), 3.60 (d, J = 14.2 Hz, 1H), 3.44 - 3.26 (m, 1H), 2.80 - 2.51 (m, 3H), 2.43 - 2.19 (m, 1H). 13 C NMR (101 MHz, CDCl₃) δ 173.6, 136.1, 129.8, 126.9, 123.6, 57.6, 54.9, 30.5, 24.1. **HRMS (ESI):** m/z calculated for [M] (C₁₁H₁₂N₄O₃S) from [M+H]⁺ is 281.0703, found 281.0698

1-phenyl-5-(((4-phenyl-1H-1,2,3-triazol-1-yl)sulfonyl)methyl)pyrrolidin-2-one (D8)

 $^{1}\text{H NMR } (400 \text{ MHz, CDCl}_{3}) \ \delta \ 8.25 \ (\text{s}, 1\text{H}), \ 7.84 \ (\text{dd}, \textit{J} = 8.1, \ 1.2 \ \text{Hz}, 2\text{H}), \ 7.53 - 7.39 \ (\text{m}, 3\text{H}), \ 7.34 \ (\text{t}, \textit{J} = 7.8 \ \text{Hz}, 2\text{H}), \ 7.29 - 7.23 \ (\text{m}, 2\text{H}), \ 7.20 \ (\text{t}, \textit{J} = 7.3 \ \text{Hz}, 1\text{H}), \ 4.82 \ (\text{ddd}, \textit{J} = 7.4, \ 6.0, \ 3.5 \ \text{Hz}, 1\text{H}), \ 3.84 \ (\text{d}, \textit{J} = 2.0 \ \text{Hz}, 1\text{H}), \ 3.68 \ (\text{dd}, \textit{J} = 14.6, \ 9.9 \ \text{Hz}, 1\text{H}), \ 2.77 - 2.45 \ (\text{m}, 3\text{H}), \ 2.15 \ (\text{tt}, \textit{J} = 12.8, \ 4.7 \ \text{Hz}, 1\text{H}). \ ^{13}\text{C NMR} \ (101 \ \text{MHz}, \text{CDCl}_{3}) \ \delta \ 173.3, \ 147.9, \ 135.7, \ 129.7, \ 129.6, \ 129.2, \ 128.3, \ 126.9, \ 126.2, \ 123.4, \ 119.3, \ 57.6, \ 54.5, \ 30.3, \ 24.0. \ \textbf{HRMS } \textbf{(ESI): } \textit{m/z} \ \text{calculated for } \textbf{[M]} \ (\textbf{C}_{19}\textbf{H}_{18}\textbf{N}_{4}\textbf{O}_{3}\textbf{S}) \ \text{from } \textbf{[M+H]}^{+} \ \text{is } 383.1172, \ \text{found } 383.1184$

(1-(4'-methoxy-[1,1'-biphenyl]-4-yl)-5-oxopyrrolidin-2-yl)methanesulfonyl fluoride (D9)

 1 H NMR (400 MHz, CDCl₃) δ 7.62 (d, J = 8.6 Hz, 2H), 7.51 (d, J = 8.7 Hz, 2H), 7.43 (d, J = 8.6 Hz, 2H), 6.99 (d, J = 8.7 Hz, 2H), 4.86 – 4.72 (m, 1H), 3.86 (s, 3H), 3.75 (ddd, J = 14.6, 4.4, 2.2 Hz, 1H), 3.43 (ddd, J = 14.5, 10.0, 2.7 Hz, 1H), 2.81 – 2.56 (m, 3H), 2.40 – 2.16 (m, 1H). 13 C NMR (101 MHz, CDCl₃) δ 173.4, 159.5, 139.7, 134.3, 132.5, 128.2, 128.0, 124.0, 114.4, 55.5, 54.9, 53.3 (d, J = 14.6 Hz), 30.3, 23.9. 19 F NMR (376 MHz, CDCl₃) δ 60.62. **HRMS (ESI):** m/z calculated for [M] (C₁₈H₁₈NO₄FS) from [M+H]⁺ is 364.1013, found 364.0999

(5-oxo-1-(4-((trimethylsilyl)ethynyl)phenyl)pyrrolidin-2-yl)methanesulfonyl fluoride (D10)

 1 H NMR (400 MHz, CDCl₃) δ 7.53 (d, J = 8.7 Hz, 2H), 7.39 (d, J = 8.6 Hz, 2H), 4.87 – 4.72 (m, 1H), 3.71 – 3.60 (m, 1H), 3.44 – 3.32 (m, 1H), 2.80 – 2.56 (m, 3H), 2.33 – 2.18 (m, 1H), 0.25 (s, 9H). 13 C NMR (126 MHz, CDCl₃) δ 173.2, 135.9, 133.4, 122.6, 121.6, 104.0, 95.5, 54.5, 52.9 (d, J = 15.0 Hz), 30.4, 23.7, 0.04. 19 F NMR (376 MHz, CDCl₃) δ 60.54. **HRMS (ESI)**: m/z calculated for [M] (C₁₆H₂₀NO₃FsiS) from [M+H]⁺ is 354.0990, found 354.0985

ethyl 5-((tert-butyldimethylsilyl)oxy)-1,2-dimethyl-1H-indole-3-carboxylate (S5)

 1 H NMR (500 MHz, CDCl₃) δ 7.60 (d, J = 2.0 Hz, 1H), 7.11 (d, J = 8.7 Hz, 1H), 6.78 (dd, J = 8.7, 2.1 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 3.63 (s, 3H), 2.73 (s, 3H), 1.45 (t, J = 7.1 Hz, 3H), 1.02 (s, 9H), 0.23 (s, 6H). 13 C NMR (126 MHz, CDCl₃) δ 166.3, 151.1, 145.7, 132.1, 127.4, 115.8, 111.5, 109.4, 103.5, 59.3, 29.7, 25.9, 18.4, 14.7, 12.0, -4.2. **HRMS (ESI)**: m/z calculated for [M] ($C_{19}H_{29}NO_3Si$) from [M+H]* is 348.1989, found 348.1985

(1-phenylpyrrolidin-2-yl)methanesulfonyl fluoride (D11)

 1 H NMR (400 MHz, CDCl₃) δ 7.28 (dd, J = 12.0, 10.9 Hz, 2H), 6.78 (t, J = 7.3 Hz, 1H), 6.61 (d, J = 8.0 Hz, 2H), 4.46 – 4.16 (m, 1H), 3.70 (dd, J = 14.6, 2.8 Hz, 1H), 3.47 (td, J = 8.6, 2.1 Hz, 1H), 3.33 – 3.11 (m, 2H), 2.32 – 1.96 (m, 4H). 13 C NMR (101 MHz, CDCl₃) δ 145.3, 129.9, 117.5, 112.2, 53.8, 52.3 (d, J = 10.1 Hz), 47.9, 30.7, 22.9. 19 F NMR (376 MHz, CDCl₃) δ 58.62. **HRMS (ESI)**: m/z calculated for [M] (C_{25} H₂₂NO₃SCI) from [M+H]⁺ is 452.1082, found 452.1088


1-(4-chlorophenyl)-5-(((2,2-diphenylvinyl)sulfonyl)methyl)pyrrolidin-2-one (D14)


¹H NMR (400 MHz, CDCl₃) δ 7.46 – 7.37 (m, 2H), 7.38 – 7.28 (m, 8H), 7.22 (dd, J = 11.0, 4.0 Hz, 4H), 6.78 (s, 1H), 4.69 (ddd, J = 13.0, 6.2, 3.8 Hz, 1H), 2.96 (dd, J = 13.4, 1.7 Hz, 1H), 2.77 (dd, J = 13.4, 10.3 Hz, 1H), 2.57 – 2.43 (m, 3H), 2.19 (dt, J = 10.6, 9.0 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 173.8, 157.0, 138.7, 135.2, 135.1, 131.4, 131.0, 129.8, 129.8, 129.6, 128.9, 128.4, 128.3, 126.9, 124.0, 56.0, 53.8, 30.6, 24.6. **HRMS (ESI)**: m/z calculated for [M] ($C_{25}H_{22}NO_3SCI$) from [M+H]⁺ is 452.1082, found 452.1088


11. References


- [1] D. C. Miller, G. J. Choi, H. S. Orbe, R. R. Knowles, J. Am. Chem. Soc. 2015, 137, 13492;
- [2] J.-B. Peng, F.-P. Wu, D. Li, H.-Q. Geng, X. Qi, J. Ying, X.-F. Wu, ACS Catal. 2019, 9, 2977;
- [3] S. Zheng, S.-Q. Zhang, B. Saeednia, J. Zhou, J. M. Anna, X. Hong, G. A. Molander, Chem. Sci. 2020, 11, 4131;
- [4] M. L. O'Duill, R. Matsuura, Y. Wang, J.L. Turnbull, J. A. Gurak, Jr., D.-W. Gao, G. Lu, P. Liu, K. M. Engle, J. Am. Chem. Soc. 2017, 139, 15576;
- [5] Y. Liu, H. Wu, Y. Guo, J. C. Xiao, Q. Y. Chen, C. Liu, Angew. Chem. Int. Ed. 2017, 56, 15432; Angew. Chem. 2017, 129, 15634;
- [6] R. Xu, T. Xu, M. Yang, T. Cao, S. Liao, Nat. Commun. 2019, 10, 3752;
- [7] J. Chen, B.-q. Huang, Z.-q. Wang, X.-j. Zhang, M. Yan, Org. Lett. 2019, 21, 9742.
- [8] C. Liu, C. Yang, S. Hwang, S. L. Ferraro, J. P. Flynn, J. Niu, Angew. Chem. Int. Ed. 2020, 59, 18435. Angew. Chem. 2020, 132, 18593;
- [9] X. Chen, J. Ren, H. Xie, W. Sun, M. Sun and B. Wu, Org. Chem. Front., 2018, 5, 184;
- [10] O. Fadeyi, M. D. Parikh, M. Z. Chen, R. E. Kyne, Jr., A. P. Taylor, I. O'Doherty, S. E. Kaiser, S. Barbas, S. Niessen, M. Shi, S. L. Weinrich, J. C. Kath, L. H. Jones, R. P. Robinson, Chembiochem 2016, 17, 1925;
- [11] C. J. Collins, M. Lanz, B. Singaram, *Tetrahedron Lett.* 1999, 40, 3673;
- [12] (a) D. F. Chen, J. C. K. Chu, T. Rovis, J. Am. Chem. Soc. 2017, 139, 14897; (b) J. C. Chu, T. Rovis, Nature 2016, 539, 272;
- [13] Z. Li, L. Song, C. Li, J. Am. Chem. Soc. 2013, 135, 4640;
- [14] F. Foschi, C. Loro, R. Sala, J. Oble, L. L. Presti, E. M. Beccalli, G. Poli, G. Broggini, Org. Lett. 2020, 22, 1402;


12. NMR Spectra of Compounds 1d, 1e, 1I-1r, 1t-1ad, 1af-1ao, 2a-2ao, D1-D14, S5






























































































































































100 90 f1 (ppm)


180


160 150 140 130 120 110


70 60


50 40


10


































































































































































































































































































































































¹³C-NMR (101 MHz, DMSO-d₆)





19F NMR (376 MHz, DMSO-d₆)
































5.0 4.5 fl (ppm)

4.0 3. 5

9.5

9.0 8.5

8.0

7. 0 6.5 6. 0


3. 0


2. 0


1.0


0.5 0.0


--1000


















¹³C-NMR (101 MHz, CDCI₃)





5.0 4.5 f1 (ppm) 4.0 3.5 3.0

2.0

1.5

1.0 0.5 0.0


6.5


6.0


5. 5


¹³C-NMR (126 MHz, CDCI₃)

8.5 8.0









5.0 4.5 fl (ppm) 3. 5

3.0 2.5

4.0

5.5

6.5 6.0

9.0


8.5 8.0 7.5


2.0


1.5

1.0


0.5










¹H-NMR (400 MHz, CDCI₃)





¹³C-NMR (101 MHz, CDCI₃)





































¹³C-NMR (126 MHz, CDCI₃)

